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palavras-chave Cancro da cabeça e pescoço, caquexia, catabolismo muscular,  
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resumo  O cancro da cabeça e pescoço é o sexto tipo de cancro mais comum no 
mundo, com 630.000 novos casos diagnosticados e mais de 350.000 
mortes registados anualmente. Os pacientes com cancro da cabeça e 
pescoço apresentam, geralmente, uma perda de peso acentuada devida, 
principalmente, à perda de massa muscular. Estes sinais de catabolismo 
estão associados a uma síndrome que se designa de caquexia. Esta 
síndrome compromete o prognóstico e a qualidade de vida do paciente 
oncológico. Apesar da sua importância clínica, não existem opções 
terapêuticas eficazes para o tratamento da caquexia associada ao cancro, 
o que pode ser justificado, pelo menos em parte, pela dificuldade em 
diagnosticar os pacientes com caquexia.  
 O objetivo desta dissertação foi caracterizar o fenótipo de pacientes com 
cancro da cabeça e pescoço com e sem perda de peso corporal e 
identificar possíveis biomarcadores de caquexia em fluidos biológicos 
para melhorar o diagnóstico e tratamento destes pacientes. Para o efeito 
estudaram-se 30 pacientes do sexo masculino com cancro da cabeça e 
pescoço que foram agrupados com base no índice de risco nutricional 
(NRI, nutritional risk index) em dois grupos: com caquexia (NRI<97,5; 
n=14) e sem caquexia (NRI>97,5; n=16). A análise de parâmetros séricos 
destacou a importância da inflamação para a caquexia e a sua associação 
com o estadio da doença. Os níveis séricos elevados de miostatina 
observados em doentes com caquexia suportam a ocorrência de 
catabolismo muscular neste grupo de doentes. Mais ainda, verificou-se 
uma correlação negativa entre os valores de proteína reativa C (CRP) e a 
grelina, o que suporta a potencial aplicação terapêutica dos agonistas de 
grelina no tratamento de doentes com perda de peso e valores de CRP 
superiores a 30 mg/dL.  A análise do proteoma da urina permitiu 
identificar 18 proteínas moduladas pela caquexia, das 520 das proteínas 
identificadas por GeLC-MS/MS, sendo de destacar as proteínas 
envolvidas na inflamação CRP, alpha chain of C4-binding protein, e 
argininosuccinato sintase. No futuro será importante validar o valor de 
diagnóstico destas proteínas para o diagnóstico da caquexia associada ao 
cancro da cabeça e pescoço e, eventualmente, de outros tipos de cancro. 
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abstract Head and neck cancer (HNC) is the sixth most common cancer 
worldwide, with estimated 630,000 new patients diagnosed annually, 
resulting in more than 350,000 deaths every year. Patients with HNC 
usually have large weight loss often associated with cachexia, a 
syndrome mainly characterized by muscle mass loss. Cachexia has been 
underdiagnosed in the set of HNC, resulting in increased rates of 
morbidity and impaired quality of life of patients. There are no effective 
therapeutic options for the management of this syndrome, which can be 
justified, at least in part, by its misdiagnosis.  
The objective of this dissertation was to characterize the body wasting 
phenotype of HNC patients and identify putative biomarkers to improve 
the early diagnosis and management of HNC cachexia. Thirty male 
patients were enrolled in this study and were assigned to one of two 
groups based on the nutritional risk index: HNC (NRI>97.5; n=16) or 
HNC+ cachexia (NRI<97.5; n=14). Targeted and nontargeted proteomic 
approaches were applied to the analysis of blood-derived serum and 
urine. Data highlighted the contribution of inflammation to the 
development of cachexia given by the high levels of C-reactive protein 
(CRP), IL-6 and TNF-α, which were associated to advanced stages of 
disease. The high circulating levels of myostatin seem to corroborate the 
occurrence of muscle wasting. The negative correlation observed 
between CRP and ghrelin suggests that HNC cachectic patients with CRP 
levels higher than 30 mg/dL may benefit from therapy with ghrelin 
agonists. Urine proteomics allowed the identification of 18 proteins 
modulated by cachexia, within the 520 distinct proteins identified by 
GeLC-MS/MS, such as alpha chain of C4-binding protein, CRP and 
argininosuccinate synthase, which emphasizes the contribution of 
inflammation to cachexia pathogenesis. Future studies will be important 
to validate the diagnosis value of these proteins for the management of 
cachexia in HNC and, eventually, in other types of cancer. 
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 Cancer is responsible for one in eight deaths worldwide, it is a leading cause of 
death in more and less economically developed countries (1,2). These numbers are 
expected to increase due to the growth and aging of the population, particularly in less 
developed countries. For this increase contributes lifestyle behaviors that are known to 
rise cancer risks, such as smoking, poor diet, physical inactivity, and reproductive 
changes (including lower parity and later age at first birth) (2). According to 
GLOBOCAN, 18,1 million new cases of cancer and 9,6 million cancer deaths worldwide 
were estimated for 2018 (3). It is anticipated that these numbers will increase in the future. 
According to the World Health Organization (WHO), from 2018 to 2040 the incidence 
of cancer will increase from 18,1 million to 29,5 million (4).  
 
1.1. Head and Neck Cancer: facts and risk factors  
 Head and neck cancer (HNC) is a malignant neoplasm that can be found in patients 
all over the world (5). HNC is the sixth most common cancer worldwide, with estimated 
630,000 new patients diagnosed annually resulting in more than 350,000 deaths every 
year (6).  In overall, the incidence of HNC cancer in males is 3.4% and mortality is 2%. 
In females, these values are lower, the incidence is 1.6% and mortality is 1% (7). For men 
aged between 60 and 80 years old, HNC is a common cause of death, worldwide; 
however, countries such as Melanesia, South Asia, parts of France, and much of Eastern 
Europe and the former Soviet republics present the highest rates (6). According to 
GLOBOCAN, the incidence of HNC will be higher in 2030 compared to 2012. The 
incidence of lip and oral cavity cancer in men is expected to increase worldwide, but the 
difference will be greater in less developed countries (more of 50%). It is also predicted 
the increase of larynx and nasopharynx cancer incidence by 2030 in the least developed 
countries, which is expected to be even greater for larynx cancer than oral cancer 
(estimated at 69.5%). Table 1 highlights the incidence of the 4 types of HNC expected 
for 2030, the values for 2012 represent an estimate of patients diagnosed in this year (8).  
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Table 1. Estimates of HNC incidence in men, in different locations, up to 2030. Differentiated 
estimates between less and more developed countries are presented (adapted from (8)). 
 World 
More developed 
countries 
Less developed 
countries 
                   Year 
Cancer type 
2012 2030 2012 2030 2012 2030 
Lip and oral 
cavity 
198,975 298,854 68,042 82,780 130,933 208,833 
Other pharynsx 115,131 175,171 44,400 52,076 731 116,737 
Larynx 138,102 216,349 50,730 62,575 87,372 148,138 
Nasopharynx 60,896 84,943 5,071 5,771 55,825 83,397 
 
 Squamous cell carcinoma (HNSCC) is the most common type of HNC, 
representing approximately 90% of the cases of HNC (9). This type of cancer affects the 
upper paranasal sinuses, nasal cavity, oral cavity, salivary gland, pharynx, and larynx 
(Figure 1) (10). HNSCC is characterized by phenotypic, etiological, biological and 
clinical heterogeneity (11). The most common symptoms are sore throat, hoarseness, 
swallowing difficulties and oral ulceration, and it depends on the location and stage of 
the tumor (12). Tumors in the head and neck are anatomically classified considering: 
primary tumor size (T), regional nodal spread (N), and distant metastases (M). According 
to the Union for International Cancer Control (UICC), the classification goes from I to 
IV and stages III and IV define a more advanced disease (13). Most patients are diagnosed 
at an advanced stage of the disease (14), and around 40% of patients are already 
malnourished prior to diagnosis (15,16). One of the etiologic factors related to HNC is 
smoking, mainly in developing countries, whereas in developed countries the human 
papillomavirus (HPV) is a major contributor to the development of oropharynx neoplasia 
(11). 
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Figure 1: Head and neck cancer subsites (adapted from (10)). 
 
Smoking is one of the most important risk factors for HNC once tobacco smoke 
contains chemicals that have cytotoxic and carcinogenic properties (12). The risk of 
developing HNC decreases about 30% 1-4 years after stop smoking, and about 60% after 
10 to 15 years (17,18). 
 Alcohol is also a risk factor for the development of HNC, which seems to be due 
to the induction of cytochrome P4502E1, the formation of ROS and cell cycle 
deregulation (19). Studies show that alcohol consumption has more impact on oropharynx 
and hypopharyngeal cancer development than on the oral cavity or larynx cancer (20,21). 
In addition, stop drinking alcohol shows benefits as significant as stop smoking; however, 
only after 20 years or more of stop drinking the risk of developing HNC decreases 
approximately 40% (17). Moreover, the combination of these two HNC risk factors 
increases the probability of developing HNC (19). 
 HPV, mainly HPV type 16 and to a lesser extent type 18, is one of the causes of 
squamous cell carcinoma of the head and neck, especially in the oropharynx (22). It is 
estimated that over 50% of oropharyngeal squamous cell carcinomas of the head and neck 
are related to HPV infection (10). The development of cancer by this virus results from 
the integration of HPV DNA into the cellular genome leading to the accumulation of 
genetic and epigenetic alterations in genes involved in the control of proliferation (19). 
Another virus, the Epstein-Barr virus (EBV), mainly affects the nasopharynx (19). 
Indeed, EBV infection is detected in 100% of non-keratinizing nasopharyngeal 
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carcinomas (23). One of the hypotheses regarding the development of cancer in the 
nasopharynx by the EVB relies on the early genetic alterations promoted in the cells of 
the nasopharyngeal mucosa by latent EBV infection (19). Finally, Herpes Simplex virus 
(HSV) is an oral cancer promoter (24). The prevalence of HSV in malignant and 
potentially malignant lesions in the oral cavity is approximately 30%. HSV is involved in 
the activation of chromosomal mutations, gene amplification and overexpression of 
preexisting oncogenes within neoplastic tissue. The contribution of HSV to oral 
carcinoma progression is supported by the perseverance of the virus in the oral mucosa 
(25). 
 Other factors such as diet, oral hygiene, environmental carcinogens, family 
history, low body mass index, exposure to ultraviolet light and preexisting medical 
conditions might also predispose to HNC. The knowledge of the factors underlying HNC 
development at the time of diagnosis might help in therapeutic decision (26).  
 Treatment of patients with HNC may differ, and treatment options should be 
individualized for each patient (27,28). Treatments usually vary between surgery, 
radiation therapy or chemotherapy (27,29). Radiation therapy (RT) is used as the primary 
treatment or adjuvant therapy to surgery. However, patients with HNC who are treated 
with RT may have several adverse effects, including anorexia, oral mucositis, changes in 
taste, dry mouth, inflammation and swallowing problems, thus contributing to 
impairment of nutritional status. These effects depend on the treated area, volume, dose 
and the type and duration of RT, and on the patient's response (27). The use of surgery 
followed by radiation therapy is generally used in early-stage oropharyngeal and 
hypopharynx cancer (30). Isolated surgery is used as the first option when cancer is 
located in the oral cavity (28). Its use always depends on the location, and so radiotherapy 
and chemotherapy are a good alternative to surgery when it is difficult to reach places or 
when vital structures such as the carotid artery are involved (29). Besides these 
therapeutic options for the management of HNC, non-pharmacological approaches such 
as exercise training is recommended to improve quality of life of HNC patients. Regular 
moderate exercise, such as walking, has beneficial effects such as on pro-inflammatory 
cytokines regulation, with impact on morbidity and mortality (31). 
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1.2. Nutritional impairment in HNC patients 
Patients with HNC are a nutritionally vulnerable group due to tumor- and treatment-
related factors, and psychological and social elements that seriously compromise their 
nutritional status (32). The tumor itself can lead to dysphagia, usually seen in patients 
with locally advanced tumors (33). In addition, it can cause pain, increased inflammatory 
activity, and altered metabolic function (32). Malnutrition and nutritional deficits have 
been associated with a negative impact on HNC mortality, morbidity and quality of life 
(34). These are worrying facts since normally up to approximately 57% of the patients 
with HNC present malnutrition with a weight loss of 10% of the basal body mass. A high 
prevalence of weight loss has been reported even before treatment (32). Patients with 
HNC who present weight loss at the diagnosis stage may present a more aggressive 
disease and usually have a worse prognosis. For example, patients with early significant 
weight loss, i.e, more than 20% loss from baseline, are more likely to die from a 
treatment-related complication. Weight loss during treatment is common and, therefore it 
is not universally prognostic (35). This may be explained by the fact that some patients 
present weight loss caused by decreased caloric intake, while the cause in other patients 
is a manifestation of a syndrome of dysregulated catabolism and anabolism (36). In fact, 
studies show that weight loss occurring in patients with HNC both at diagnosis and during 
treatment is primarily a result of a loss of lean body mass, and cannot be reverted by 
parental nutrition (37,38). In addition, several studies have demonstrated the importance 
not only of weight but of changes in body composition throughout cancer treatment  
(39,40). Therefore, weight loss in HNC patients is usually associated with a syndrome 
called cachexia.  
 
1.3. HNC cachexia-related muscle wasting: circulating mediators and 
signaling pathways 
 Cachexia is “a multi-factorial syndrome defined by an ongoing loss of skeletal 
muscle mass (with or without loss of fat mass) that cannot be fully reversed by 
conventional nutritional support and leads to progressive functional impairment” (41). 
Cachexia is an underexplored syndrome in the set of HNC (42), being associated with 
increased rates of mortality, morbidity and impaired quality of life in patients with 
HNSCC (43). Cachexia is characterized by decreased appetite, weight loss, metabolic 
alterations and inflammatory state (43). In addition, patients present decreased physical 
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performance, which impairs their quality of life and the clinical outcome of disease 
treatment (44). More than half of cancer patients suffer from cachexia at the time of death. 
Initially, it was estimated that cachexia contributes to cancer death in approximately 20% 
(34); however, there is no consensus in the literature (35,36). For instance, percentages 
of 20% or higher were reported in HNC patients (32). Cachexia is hardly diagnosed in 
early stages, i.e., in pre-cachexia stages, which are characterized by involuntary weight 
loss lower than 5% up to 6 months, and/or by metabolic changes, such as increased 
proteolysis, increased lipolysis, increased resting energy expenditure and insulin 
resistance (31,32). However, cachexia is already established when there is an 
unintentional weight loss of at least 5% over 3 to 6 months or weight loss > 2% over 6 
months in individuals with a body mass index < 20 kg/m2 in absence of simple starvation 
or the presence of sarcopenia (37,38). The identification of patients in the initial stage of 
cachexia is essential for early interventions (45). Thus, it is very important to understand 
the molecular pathways and mediators involved in the pathogenesis of cachexia and to 
know how to identify this syndrome. Mediators of systemic inflammation have been the 
most recognized cachexia markers, especially acute phase response proteins (45). Some 
cytokines such as interleukin (IL) -1β, IL-6, IL-8, tumor necrosis factor-α (TNF-α), and 
Interferon-gama (IFN-γ) have already been linked to the cachexia pathogenesis in some 
cancers such as esophagus, pancreas, lung, and prostate. In addition, cachexia may result 
from the deregulation of neuropeptides, such as α-melanocyte stimulating hormone, 
neuropeptide Y, melanocortin, and corticotrophin-releasing factor (46). Richey et al. 
reported an association of IL-6 and C-reactive protein (CRP) with cachexia in patients 
with HNSCC (46). The cytokines IL-1β, IL-6, IFN- and TNF-α have also been associated 
with muscle wasting (47). This cancer-related inflammation has been related with the 
communication between the host and tumor cells. This interaction usually results in 
systemic alterations, immune suppression and evasion, and malignant progression (48). 
Indeed, the increase in CRP is associated with tumor proliferation, increased metastases 
to lymphatic, and worse prognosis (49). In contrast, in a study conducted by Wittenaar et 
al. no marked inflammatory activity was observed in patients with cachexia, compared 
with the ones without cachexia (42). Indeed, it has been noticed a variability in 
inflammatory activity in patients with advanced cancer stage across studies in literature 
(46,50). 
 9 
 
 Cachexia seems to result from the activation of some pathological muscle wasting 
mechanisms, with inflammation and oxidative stress being the triggering players of the 
imbalance between protein synthesis and breakdown (51,52). The best defined anabolic 
pathway in skeletal muscle involves the activation of the serine/threonine kinase Akt that 
results in the activation of the mammalian target of rapamycin (mTOR) (52). However, 
the activity of this pathway is reduced, if not abolished, in catabolic diseases, such as 
cancer cachexia (53). In overall, the molecular pathways associated to muscle catabolism 
are: (a) the ubiquitin-proteasome pathway and caspases under transcriptional control of 
the transcription factors forkhead O (Fox-O) and nuclear factor (NF) -kB (54); (b) the 
myostatin (Mstn) pathway (55), which acts locally as a negative regulator of the 
Akt/mTOR pathway and by the decreasing the number of satellite cells; (c) muscle 
apoptosis (56); (d) autophagy/lysosomal activity (57). The molecular triggers and the 
signaling pathways under their control in skeletal muscle are critically analyzed in the 
following subsections. 
 
1.3.1. Interleukin-6 
 IL-6 is a glycoprotein, mainly produced as an acute-phase protein by the liver and 
it is related to the development of cachexia. In addition, some tumors secrete IL-6; 
however, this cytokine is predominantly secreted by immune cells. It is involved in the 
amplification of inflammatory cascades in the immune response. Elevated levels of this 
protein are detected in patients who have cancer cachexia (31,47,58). High levels of IL-6 
have been reported in HNSCC (59–62). Moreover, IL-6 concentration seems to increase 
as tumor stage progresses, with significant differences detected between stage IV and 
previous stages of cancer (62).  
 The IL-6 signaling mechanism begins by its binding to an 80 kDa type 1 cytokine 
alpha receptor subunit designated IL-6R or CD126 and to 130 KDa, gp130 forming an 
IL-6/ IL-6R/gp130. From this complex different signaling pathways can be followed, 
such as the JAK/STAT3 pathway or the PI3K/Akt, Ras/MAPK and Wnt signaling 
pathways (63). The activation of JAK/STAT3 seems to explain the loss of muscle mass 
in cachexia (64,65).  
 Muscle atrophy in cancer cachexia besides being caused by increased protein 
degradation is also caused by decreased protein synthesis. Inhibition or down-regulation 
of the PI3K/Akt/mTOR pathway is linked to decreased protein synthesis. IL-6 in 
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conjunction with serum amyloid-A (SSA), increases SOCS3 expression in muscle. This 
molecular player leads to the down-regulation of IRS-1. Since the PI3K/Akt signaling 
pathway requires the initial activation of IRS-1, this pathway is inhibited by SOCS3 and 
so protein synthesis decreases (64). The role of IL-6 on proteolysis was corroborated by 
studies that injected IL-6 into rodents observed muscle protein breakdown, while when 
IL-6 receptor antibody was administered muscle atrophy was prevented (66–68). 
 The IL-6/gp130/JAK/STAT3 pathway has been associated with cachexia. IL-6 
initiates STAT3 activation by binding to gp130 and activating JAKs that phosphorylates 
STAT3. In addition to IL-6, STAT3 can be activated from leptin through the homologous 
receptor to gp130. STAT3 can also be activated by tyrosine kinase receptors such as 
epidermal growth factor (EGF), platelet-derived growth factor (PDGF), among others 
(65). Following the phosphorylation of STAT3, spontaneous dimerization of this 
transcription factor occurs. This pathway ends with the phospho-STAT3 being 
translocated to the nucleus where the dimers bind to the consensus sequences on the 
promoter regions of target genes with the resultant cascade of gene (69) (Figure 2). To 
date, the mediators involved in the activation of STAT3, the IL-6 family are the best 
characterized in cancer cachexia, especially the IL-6 itself. It has already been shown that 
IL-6 is enough to induce weight loss in rats (70). In addition, the STAT3 phosphorylation 
increases with the severity of cachexia and serum concentrations of IL-6 (71). On the 
other hand, in another study, mice with muscle-specific deletion of gp130 and Lewis lung 
carcinoma cachexia had reduced muscle loss and reduced pSTAT3 (72). The results 
obtained by this study are like those of a study where cachexia associated to intestinal 
cancer was treated with IL6R neutralizing antibodies (73). 
 In HNSCC, the activation of STAT3 seems a common event; however, STAT3 
mutations with gain-of-function were not observed, neither activating mutations in the 
EGFR or JAK receptors (69). Therefore, the positive regulation of STATs seems to be 
done through the activation of cytokine or growth factors receptors or by the negative 
regulation of protein tyrosine phosphatase receptors (PTPR). Thus, hyperactivation of 
STAT3 may be a consequence of upregulation of upstream signaling players, such as IL-
6 or of decreased activity of upstream negative effectors (74,75). So, STAT3 signaling 
might be a target for the development of HNSCC therapy. The interruption of this 
pathway could be made by: (i) inhibiting upstream receptors and thereby reducing 
phosphorylation; (ii) inhibiting the pSTAT3 SH2 domain, blocking dimerization; (iii) 
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inhibiting STAT3-DNA binding, thus preventing target gene transcription; and (iv) by 
inhibiting STAT3 transcription, to modulate total expression of STAT3 (69). 
 
 
Figure 2. Signalling pathways modulated by cancer in skeletal muscle that results in muscle wasting. In 
IGF-1 / Akt / mTOR signaling pathway, occurs phosphorylation of the IRS insulin receptor after binding of 
IGF-1 to IGF1R results in the activation of PI3K / Akt signaling, which upon activation of mTOR culminates 
in the protein synthesis. The Myostatin and Activin A signaling depends initially on the binding of one of 
the mediators (Activin or Myostatin) to the common receptor, ActRIIB on the muscle membrane, resulting 
in its dimerization and subsequent recruitment and activation of type 1 receptors. Next, SMAD2/3 
phosphorylation takes place, on the part of type 1 receptors, that recruits SMAD4. The complex formed is 
translocated to the nucleus leading to transcriptional changes that result in protein degradation. On the 
other hand, SMAD2/3 phosphorylation suppresses the FoxO3 phosphorylation that is translocated to the 
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nucleus and contributes to protein degradation through the activation of the MuRF-1 and Atrogin-1 genes 
and autophagy. In addition, SMAD2/3 phosphorylation reduces the activity of Akt without protein synthesis. 
In case of JAK/STAT3 signaling pathway, this is active after IL-6 binding to the receptor following 
induction to gp130 homodimerization. After phosphorylation of STAT3, a dimer is formed which is 
translocated to the nucleus which results in the increase of atrogin and MuRF1 culminating in protein 
degradation. In addition, TNF-α and IL-1 also activate ubiquitination from activation of the IKK complex. 
The complex phosphorylates the IkBa proteins and the NF-kB is translocated to the nucleus, where 
ubiquitination and protein degradation are activated, resulting in the loss of skeletal muscle mass. Figure 
produced using the Servier Medical Art. 
 
1.3.2. Tumor necrosis factor-α 
 TNF-α plays central roles in inflammation, apoptosis, and development of the 
immune system (76). It is released by activated macrophages and other cells such as 
CD4+, neutrophils, mast cells, eosinophils, and tumor cells (77). The mechanism of action 
remains largely puzzling, it is only known that TNF-α can stimulate catabolism via 
indirect mechanisms (78). These mechanisms may involve alteration of circulating levels 
of hormones that regulate muscle growth and affect tissue sensitivity to such factors, 
stimulation of catabolic cytokine production, induction of anorexia (weight loss, loss of 
appetite, increased thermogenesis) and alterations of carbohydrates, proteins and lipids 
metabolism (78,79). Llovera et al. reported an increase of skeletal muscle protein 
degradation in rats after TNF-α administration (80). The same effect was observed by 
others in genetically modified mice with no TNF-α receptor protein type I and in wild-
type mice transplanted with Lewis lung carcinoma (81). 
 TNF-α is a cytokine that contributes to cachexia by increasing corticotrophin 
releasing-hormone (CRH) levels and decrease food intake (77). It also participates in the 
recruitment of inflammatory cells that contribute to the degradation of muscle tissue 
proteins (82). TNF-α also promotes muscle mass loss by inducing apoptosis of muscle 
fibers (83). In addition, high levels of TNF- α have been related to the short survival time 
of patients with HNSCC (84). This evidence contributes to the hypothesis that higher 
levels of TNF-α are characteristic of patients with HNC cachexia (85).  
 TNF-α stimulates the degradation of myofibrillar proteins, which was more 
notorious in the soleus muscle of rats after acute treatment with recombinant TNF-α. The 
same was not observed in the extensor digitorum longus muscle (86). It has already been 
demonstrated that protein redistribution and marked depletion of muscle protein occurs 
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only after a long treatment with recombinant TNF-α (87). The role of TNF-α in protein 
degradation occurs mainly through the catabolic nuclear factor kappa B (NF-kB) 
signaling (88). NF-kB plays an important role in regulating the ubiquitin-proteasome 
system (UPS), which is the principal mechanism of protein degradation in muscle cells. 
Besides being regulated by NF-κB signaling, the UPS is further regulated by O-protein 
FoxO, p38, mitogen-activated protein kinase (MAPK) and STAT3 (89). TNF-α promotes 
NF-kB activation in the skeletal muscle through the activation of the type 1 TNF- α 
sarcolemmal receptor (TNFR1) (90). Consequently, protein kinase C (PKC) is activated 
and results in the rapid conjugation of ubiquitin to muscle proteins (85,90,91). All these 
processes lead to the proteasomal degradation of I-kBa, releasing NF-kB subunits from 
its inhibitory effect. Then, NF-kB dimers translocate to the nucleus (85), where regulates 
the expression of genes from the UPS. The proteins selected to be broken down will be 
ubiquitinated, i.e., are marked by covalent linkage of a chain of ubiquitin molecules to an 
internal lysine on the protein. Later, ubiquitinated proteins are recognized and degraded 
by the proteasome in smaller peptides. This process is regulated by three types of 
enzymes: the ubiquitin-activating enzyme (E1), the ubiquitin conjugating enzyme (E2) 
and the ubiquitin ligase (E3). E1 is the enzyme that initiates the pathway of the ubiquitin-
proteasome, since the first step is the activation of the ubiquitin monomers and their 
linked to E1, then they are transferred to E2, and from there they can interact with an E3 
and transferred to the substrate protein (64). E3 is the key enzyme in the UPS, in fact, its 
function is to bind the activated ubiquitin to the lysine residues on the protein substrate 
and confers specificity to the system. The E3 ubiquitin ligases responsible for the 
degradation of the skeletal muscle protein are atrogin-1, also referred to as 
MAFbx/Atrogin, and muscle RING finger protein 1 (MuRF1). The targeted deletion of 
atrogin-1 and/or MuRF1 showed reduction of muscle atrophy, confirming its role in the 
skeletal muscle-wasting (54). In the end, after interaction with E3 and transfer to the 
substrate protein the proteins that were ubiquitin-marked are degraded by the 26S 
proteasome complex (20S core catalytic complex and one or two 19S regulatory 
complexes). The 19S regulatory complex is responsible for substrate recognition (64). 
Cai et al. demonstrated that NF-κB activation resulted in muscle wasting in transgenic 
skeletal muscle selective IKKβ mice. E3 ligase MuRF1 was also shown to be increased 
in these mice (92). Thus, when there is an increase of TNF-α the UPS is stimulated in 
excess, culminating in the loss of muscle mass (Figure 2). So, TNF-α can promote protein 
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degradation, with its mediators being NF-kB. Despite its role in promoting muscle 
wasting, many patients with HNC-related cachexia showed unchanged circulating levels 
of TNF-α, suggesting that this cytokine is a poor prognostic marker of cachexia.  
Moreover, TNF-α inhibition did not result in the stop or in the reverse of cancer cachexia 
(93). 
 
1.3.3. Interleukin-1 
 IL-1 is a pleiotropic pro-inflammatory cytokine involved in tumor growth and 
metastasis. Within the IL-1 family, there are three members that bind to the same receptor, 
IL-1α and IL-1β, two active members and the third member is an antagonist, IL-1Ra (94). 
The IL-1 pathway is involved in inflammatory responses, its role is to regulate the 
expression of various inflammatory genes in immune cells. The IL-1 pathway is activated 
when one of the agonists, IL-1α or IL-1β, binds to the IL-1 receptor (IL-1R1). This IL-1 
signaling pathway has been associated with tumor growth, angiogenesis, metastasis, and 
cancer cachexia. This association occurs due to the role of this pathway in the expression 
of various proinflammatory cytokines, including IL-1, IL-1β, IL-6, IL-8, involved in 
tumor survival, and is involved in the infiltration of several immune cells in the tumor, 
which increases the inflammatory and pro-survival microenvironment of the tumor (95). 
In addition to TNF-α, IL-1 is an activator of NF-κB. There is evidence of aberrant 
constitutive activation of NF-kB in the HNSCC tumor cells. By regulating the activation 
of NF-kB and also by triggering the cascade expression of chemokines/cytokines detected 
in SCC, IL-1 initiates proinflammatory responses. In addition, IL-1 can function as an 
autocrine factor, i.e., it stimulates tumor fibroblasts to produce IL-6, IL-8, GM-CSF, 
VEGF, and a paracrine factor to stimulate HGF production by stromal fibroblasts (96). 
Elevated levels of IL-1 produced by tumor cells have been associated with poor prognosis 
(97) and with increased risk of distant metastasis (98).  
 IL-1 has also been associated with HNC cachexia (47,99), which seems to involve 
the activation of NF-kB signaling in skeletal muscle (100). IL-1 concentrations increase 
in cachexia and their effects are like TNF-α relative to the NF-kB pathway (93). That is, 
IL-1 binds to its IL-1R receptor, activating the IKK complex, which phosphorylates the 
IkB (NF-κB inhibitors) proteins, marking them for poly-ubiquitination and proteosomal 
degradation releasing the NF-κB which activates MuRF1 and atrogin-1, two ligases that 
promote protein degradation (Figure 2) (101). Moreover, IL-1 induces anorexia in 
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cachectic patients, as it induces an increase in tryptophan concentrations, which leads to 
increased levels of serotonin, since it is its precursor. Serotonin may play a role in the 
development of cancer cachexia since it seems to regulate the appetite at the hypothalamic 
level (102). Plasma levels of IL-1β have been shown to better reflect the characteristics 
of cachexia (weight loss and sarcopenia) than IL-6. They have been associated with 
weight loss, sarcopenia, asthenia, and loss of appetite (103). 
 
1.3.4. C-reactive protein 
 CRP is an acute phase protein and functions as a marker of inflammation, not only 
acute but also chronic (104,105). Its synthesis occurs in hepatocytes and can be regulated 
by proinflammatory cytokines, including IL-1, IL-6, and TNF-α (104). In HNC patients, 
an association between elevated CRP, TNF-α, and IL-6 has been demonstrated (106–
108). Therefore, when there is an abundance of proinflammatory cytokines in the tumor 
microenvironment, this can potentiate angiogenesis, favoring neoplastic growth. Patients 
with malignant tumors normally have high serum CRP content, which highlights a close 
connection between inflammation and malignancy (105). Patients with oral squamous cell 
carcinoma and elevated serum CRP levels before treatment presented a worse prognosis, 
with nearly all patients surviving at most 5 years, whereas patients with normal CRP 
levels had survived after 5 years of surgical resection (109). In addition to promoting 
neoplastic growth, elevated CRP has been positively correlated with weight loss and 
cancer cachexia (110,111). Its association to muscle loss seems to be explained by the 
contribution of skeletal muscle in supporting other tissues with free amino acids to sustain 
their protein synthesis, namely the synthesis of acute phase proteins in the liver, including 
CRP. An example of such an amino acid is glutamine, a non-essential amino acid, which 
is released by skeletal muscle in order to provide energetic substrate and precursor to 
nucleic acid synthesis for rapidly dividing cells, the immune system, and the intestinal 
mucosa. Glutamine is also a primary source of nitrogen that supports tumor cells 
proliferations once supports protein and DNA synthesis, being also a source of energy 
(112,113). Alanine is other example of an amino acid exported in large quantities from 
skeletal muscle and used for the synthesis of proteins in other tissues. This amino acid 
also supports liver gluconeogenesis, being an energetic substrate of tumor cells. In an 
inflammatory situation, the muscle becomes inefficient to provide enough amino acids to 
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the entire body, eventually resulting in catabolism (93,114). So, the large amounts of 
glutamine and, indirectly, alanine, that the tumor consumes along with the use of these 
amino acids for the synthesis of the acute phase proteins have a synergistic effect on the 
loss of muscle mass. 
 
1.3.5. Myostatin and Activin-A 
 Activin-A (ActA) is a homodimer of β-Activin chains, belonging to the TGF-β 
superfamily. The concentrations of ActA increase in circulation with acute inflammation, 
acute respiratory failure, renal failure and in some cancers, especially in cancers with 
bone metastases (115). Activin may be present in the circulation in bioactive free form or 
bound to Follistatin (116). There is evidence that inhibition of ActA results in reversal of 
cachexia and thereby increases survival in animal models identified with cancer cachexia 
(117). In HNC, high expression of ActA has been associated with a more aggressive 
tumor, since the high expression of ActA is correlated with tumor differentiation, 
metastasis, survival, and recurrence (116). 
 Mstn is also a member of the TGF-β superfamily and is involved in the negative 
regulation of skeletal muscle growth and differentiation. Mstn is secreted by murine and 
human neoplasms and so, this cytokine was proposed to be a novel tumoral factor that 
stimulates skeletal muscle wasting during cachexia (118). High circulating levels of Mstn 
were reported by several authors in muscle wasting conditions (119–122). However, 
contradictory results were described. Loumaye et al. reported lower plasma 
concentrations of Mstn in cachectic patients when compared with non-cachectic patients 
(115). So, the role of Mstn on HNC cachexia is still elusive. 
 ActA is believed to replicate the biological action of Mstn on the skeletal muscle 
since they share the same receptor (115). The mechanism of action of Mstn and ActA in 
skeletal muscle is shown in Figure 2. The released Mstn or ActA binds to the receptor B 
of the membrane activin type II (ActRIIB). After binding of Mstn or ActA, ActRIIB 
undergoes dimerization, with recruitment to the membrane of type I receptor (ActA: 
ALK4 or 7; Mstn: ALK5 or 7). The already activated type I receptor phosphorylates 
SMAD2/3 which forms a complex with SMAD 4 and this complex will regulate the 
transcriptional responses that result in the loss of muscle mass. In addition, Mstn and 
ActA succeed in suppressing the activity of Akt, therefore the activity of mTOR resulting 
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in decreased protein synthesis. This Akt inhibition has another consequence since Akt 
can phosphorylate and inactivate the O-proteins of the graph box (FOXOs: FoxO1, 
FoxO3, and FoxO4) and these are exported from the nucleus to the cytoplasm. With Akt 
activity inhibited FoxO3 is not phosphorylated, ie it is translocated to the nucleus. In this 
way, they will contribute to the loss of muscle mass since they are involved in the 
transcriptional regulation of autophagy that promotes the ubiquitination and degradation 
of proteins (101). 
 
1.4. Strategies for the management of HNC muscle wasting targeting 
the molecular mediators involved 
 Cancer cachexia is a highly incident syndrome in patients with HNC and of great 
clinical importance. However, there are no broadly adopted guidelines to standardize its 
management. To aggravate the situation, there is a lack of effective pharmacological 
interventions for the treatment of this syndrome. Currently, the approaches used are 
mainly non-pharmacological, such as nutritional education, support, and exercise. Some 
pharmacological agents have been recommended as corticosteroids and progesterone 
analogs; however, the positive effects are mainly at the anorectic level, and their clinical 
use is limited due to its side effects. In this way, efforts have been made in the attempt to 
develop novel strategies for the management of this syndrome. Some agents have already 
been studied, including ghrelin analogs and anti-cytokines, the latter being previously 
seen as possible mediators in HNC cachexia (123).  
 Cytokine inhibitors or anti-cytokines may be potential effective agents in the 
treatment of HNC cachexia. Inflammation is one of the main promoters of cachexia and 
these agents may be potentiating modulators of inflammatory catabolic conditions (124). 
Pro-inflammatory cytokines, including TNF-α, IL-1, and IL-6 are the main interveners 
under pathophysiological conditions that leads to chronic inflammation and loss of 
skeletal muscle. Their presence in large concentrations in the blood of patients with 
cachexia makes them potential targets of treatment in patients with HNC cachexia. That 
is, antibodies against these cytokines may have a positive effect on the regulation of 
skeletal muscle loss in patients with HNC cachexia (125). Some examples of the anti-
cytokines drugs are thalidomide, clazakizumab, MABp1, IP-1510, among others (123). 
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Thalidomide is a derivative of glutamic acid, this agent has already been shown 
to have anti-inflammatory, immunomodulatory, anti-angiogenic, sedative and anti-emetic 
effects. Its action has been extensively studied, since this agent appears to involve the 
suppression of several cytokines, including TNF-α and IL-6, but also angiogenesis 
mediators, such as VEGF and FGF, inhibition of NF-κB and downregulation of COX-2 
(123,125). Besides, thalidomide was reported to reduce serum levels of CRP in patients 
with cachexia (125). In contrast with some anti-cytokines agents, thalidomide has been 
shown to be well tolerated (126,127). Even, the effectiveness of thalidomide in the 
treatment of cachexia is questionable, and further studies are needed. Putative anti-TNF 
strategies for the treatment of cancer cachexia, such as pentoxifylline, etanercept, 
infliximab, and melatonin, have been studied and suggested (123). Administration of anti-
murine TNF IgG has been shown to down-regulate the levels of circulating TNF in rats 
(128). Regarding IL-6, it has been observed that the IL-6 inhibition contributes to the non-
development of cachectic features. Then, it became an interest to target this pro-
inflammatory factor in the clinical setting. The humanized monoclonal antibody 
clazakizumab (ALD518), the only specific anti-IL-6 agent, has been evaluated in clinical 
trials in the treatment of cancer cachexia (123). ALD518 is well tolerated, with minimal 
adverse effects (101). And, therefore, it could be a potential agent to introduce in the 
management of HNC cachexia; however, these putative beneficial effects must be 
confirmed. IP-1510 is a synthetic peptide IL-1 receptor antagonist. However, limited 
efficacy and toxicity for cancer cachexia has been reported (129). MABp1 is more 
specific because it is a natural IgG1k human monoclonal antibody targeting IL-α, since it 
is an early mediator of the inflammatory response (123). MABp1 has been shown to be 
well tolerated, effective on body composition and seems to have antitumor effects. 
Despite these promising results in patients with cancer cachexia, this antibody has been 
shown to cause proteinuria (130). 
 As noted above, Mstn and ActA inhibit muscle growth and promote muscle 
protein loss. And, therefore, they can also be two therapeutic targets for the treatment of 
cancer cachexia. And in this way, two human monoclonal antibodies against myostatin, 
bimagrumab (BY338), and trevogrumab (REGN1033), have been studied. The first 
showed potential to increase the differentiation of primary human skeletal myoblasts and 
to increase the skeletal muscle mass in mice since it can block the ActRIIB receptors 
(125). The BY338, in addition to binding to the ActRIIB receptor, has more affinity than 
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the natural ligands Mstn and ActA (131). Despite its success in the animal model, there 
is a lack of studies in humans to assess its effectiveness and absence of adverse effects. 
REGN1033 has high affinity and specificity for myostatin. It has been shown to increase 
muscle strength in young and old mice, and to prevent muscle mass loss, accelerate 
muscle mass recovery and promote better physical performance in combination with 
exercise in mice (132). Again, its disadvantage is that all these characteristics were 
observed only in animal models. 
 Other agents that have also been studied as a strategy for the management of 
cancer cachexia were ghrelin analogs (123). The clinical use of ghrelin becomes even 
more difficult because ghrelin has a short half-life and parenteral dosage form. In this 
way, other options have been investigated. A ghrelin receptor agonist called anamorelin 
has advantages over ghrelin as it can be administered orally and has shown positive 
effects on appetite and lean body mass (124). However, despite increasing muscle mass 
this ghrelin agonist does not increase muscle strength. This result is not surprising, since 
ghrelin increases muscle mass by increasing growth hormone, which not modulates 
muscle strength. Despite this, its use in the treatment of cancer cachexia should not be 
totally ruled out once it improves appetite and, thus, the anorexia usually seen in patients 
with HNC cachexia (133). Therefore, the use of anamorelin for the treatment of cancer 
cachexia should better explored to assess efficacy and long-term safety (124).
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The general objective of this dissertation was to characterize the muscle wasting 
phenotype of HNC patients and identify putative biomarkers to improve the early 
diagnosis and management of muscle wasting in this group of patients. To accomplish 
this aim, serum and urine samples were collected from patients with HNC, with and 
without body weight loss, for proteome characterization using target and non-target 
strategies. Immunoblotting and mass spectrometry-based approaches were used for the 
identification of the biological processes involved in HNC-related body wasting and the 
underlying proteins. 
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3.1. Patients selection 
Thirty male patients (aged 43–77 years) diagnosed with head and neck cancer 
were enrolled in the present study, which was conducted between September 2018 and 
June 2019. Study protocol was approved by the Ethics Committee from the Instituto 
Português de Oncologia do Porto. The nature and purpose of the study was explained to 
participants before written informed consent was obtained. The eligibility criteria 
included patients: i) no obese and no diabetic; ii) no prior history of cancer; iii) with 
spinocellular tumors; iv) not submitted to prior cancer treatment; v) able to do unrestricted 
physical activity. Clinicopathological data was obtained from patients’ clinical records. 
Among the information gathered by physicians from the Instituto Português de 
Oncologia do Porto was age, smoking and drinking habits, medication and tumors’ stage, 
nutritional information regarding body mass index (BMI) and Malnutrition Universal 
Screening Tool (MUST), shown in Table 2. In addition, biochemical data from serum 
analysis (C-reactive protein (CRP), albumin, glucose, urea, cholesterol, and triglycerides) 
were provided. The reference values are shown in Supplemental Table S1. HNC tumours 
were histologically classified according morphologic characteristics that allow the 
identification of histogenesis of the tumor as epidermoid/squamous (134). Blood and 
urine samples were collected from the enrolled patients and prepared for targeted and 
non-targeted proteomic approaches, as described in the Figure 3.  
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Table 2. Clinical and pathological data of the patients included in the study.  
Gender, n (%) 
Male 30 (100.00) 
 Smoking habits, n (%)  
None 0 (0) 
Previously smoked 7 (23.33) 
Smoker 23 (76.67) 
Alcoholic habits, n (%)  
None 6 (23.33) 
Light 2 (6.66) 
Moderate 4 (13.33) 
Marked 16 (53.33) 
Chronic 1 (3.33) 
BMI, n (%)  
Underweight (<18.5 Kg/m2) 11 (36.67) 
Healthy weight (18.5 – 25 Kg/ m2) 17 (56.67) 
Overweight (>25Kg/ m2) 2 (6.67) 
Location of the tumor, n (%)  
Tongue 8 (28.57) 
Pharynx 10 (35.71) 
Larynx 3 (10.71) 
Laryngeal Pharynx 6 (21.43) 
Vocal cord 1 (3.57) 
Tumor staging, n (%)  
st
a
g
e 
T
 
0 0 
1 3 (10.34) 
2 2 (6.90) 
3 9 (31.03) 
4 15 (51.72) 
st
a
g
e 
N
 0 8 (27.59) 
1 1 (3.45) 
2 16 (55.17) 
3 4 (13.79) 
MUST score, n (%)  
0 9 (34.62) 
1 4 (15.38) 
2 7 (26.92) 
3 3 (11.54) 
4 3 (11.54) 
There was no information for one patient about tumor location and other patient had 3 tumors 
(nasopharynx, pyriform sinus, and lung). The latter patient was further removed from the information on 
tumor staging. For the MUST score, information was missing for 4 patients. The n represents the number 
of individuals considered in each parameter. 
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Patients were initially assigned to one of two groups according to the percentage 
of body weight loss reported in the last 6 months. Patients that reported a weight loss 
higher than 5% were included in the head and neck cancer + cancer cachexia 
(HNC+Cachexia; n=20) group whereas patients with no weight loss or weight loss lower 
than 5% in 6 months were included in the head and neck cancer with no cachexia (HNC; 
n=10) group. After the analysis of experimental data and considering previous findings 
on the evaluation of body wasting (135), patients were redistributed based on nutrition 
risk index (NRI), described below. According to this distribution, 16 patients were 
assigned to HNC group and 14 patients to HNC+Cachexia group.  
 
 
Figure 3. Schematic representation of the experimental procedure. Serum and urine samples were collected 
from patients. Serum was used for the immunoblot analysis of protein targets whereas urine proteome was 
characterized by GeLC-MS/MS.  
Legend: CRP: C-reactive protein; HNC: head-and-neck cancer; IL: interleukin; TNF-α: tumor necrosis 
factor alpha; MMP: metalloproteinase; MS: mass spectrometry. Figure produced using the Servier 
Medical Art. 
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3.2. Nutritional risk assessment 
Nutritional risk was assessed through the application of the Nutritional Risk Index 
(NRI) tool developed by the Veteran Affair Total Parenteral Cooperative Study Group 
(136). This is a tool with high sensitivity and specificity (137,138). The NRI is determined 
using the values of serum albumin, and of the actual and usual percentage weight, based 
on the following equation: 
𝑁𝑅𝐼 = 1.519 𝑥 𝐴𝑙𝑏 𝑠𝑒𝑟𝑢𝑚 (
𝑔
𝑑𝐿
) + 0.417 𝑥 (
𝑎𝑐𝑡𝑢𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
𝑢𝑠𝑢𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 
 𝑥 100). 
The following criteria were used for the analysis of results: above 100 indicate 
satisfactory nutritional status; between 97.5 and 100, mild risk of malnutrition; from 83.5 
to 97.5, moderate risk; and below 83.5, severe risk.  
Patients with NRI equivalent to a satisfactory nutritional status or mild risk were 
considered without cachexia and, thus included in the HNC group. Patients with moderate 
or severe risk were considered with cachexia and included in the HNC+Cachexia group. 
 
3.3. Immunoblot analysis of Serum samples 
 
Blood samples were collected in the morning at IPO-Porto. No fasting was 
required to patients. Blood samples were allowed to clot for one hour and then centrifuged 
at 4000g for 10 minutes. The supernatant was collected and stored at 20ºC until the 
analysis of some molecular markers by immunoblot analysis performed according to 
Caseiro et al. (139) with slight modifications.  
Samples were diluted (1:50) in Tris-buffered saline (TBS; 10 mM Tris, pH 8.0, 
0.15 M NaCl). Then 50 μL of each of these samples were blotted onto a nitrocellulose 
membrane (Amersham™ Protran™, GE Healthcare, Germany, 0.45 μm porosity) under 
vacuum, followed by Ponceau S staining for protein loading control. Nonspecific binding 
was blocked with 5% (w/v) nonfat dry milk in TBS with 0.05% of Tween 20 (TBS-T), 
during 1 hour at room temperature with agitation. Next, the membranes were incubated 
with the corresponding primary antibody, diluted 1:1000 in 5 % (w/v) nonfat dry milk in 
TBS-T for 1 hour at room temperature and with agitation. The primary antibodies used 
were: rabbit polyclonal anti-ghrelin (ab64325), rabbit polyclonal anti-IL-6 (ab6672), 
rabbit polyclonal anti-myostatin (ab98337), rabbit polyclonal anti-C reactive protein 
(CRP; ab32412), mouse monoclonal anti-TNF-α (ab1793), rabbit polyclonal anti-
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metalloproteinase (MMP) 2 (ab37150) and rabbit polyclonal anti-MMP9 (ab38898) from 
Abcam® (Cambridge, UK). Then, the membranes were washed 3 times (10 minutes each) 
with TBS-T and incubated with the appropriate secondary horseradish peroxidase-
conjugated antibody (anti-mouse or anti-rabbit, NA931 or NA934, respectively; GE 
Healthcare, UK), diluted 1:1000 in 5% (w/v) nonfat dry milk in TBS-T for 1 hour at room 
temperature with agitation. Membranes were then washed 3 times with TBS-T (10 
minutes each). Immunoreactive bands were detected with ECL reagents 
(WesternBright™ ECL, advansta, CA, USA) using the ChemiDoc Imaging System 
v.2.3.0.07 (Bio-Rad®, CA, USA) and the images obtained were analyzed with Image Lab 
software (Bio-Rad®, CA, USA, version 6.0.0,). The optical densities obtained were 
expressed in arbitrary units. 
 
3.4. Proteomic characterization of urine samples  
Patients provided one sample of urine collected in the morning, during their interview 
at IPO-Porto, collected on the same day of blood samples. Urine was centrifuged for 10 
min, at 4000×g, 10-12°C. Then, 800 µL of the supernatant was passed through 10-kDa 
filters (Vivaspin, Sartorius), as previously reported (140). The retentate was resuspended 
in resuspension buffer (10% SDS and Tris buffer 0.5 M, pH 6.8). The protein content in 
the concentrated and desalted urine samples was assayed with the commercial kit RC 
DCTM Protein Assay (Bio-Rad®, Hercules, CA, USA), according to the manufacture’s 
recommendations and using bovine serum albumin (BSA) as protein standard. A 
calibration curve with standard solutions of BSA at concentrations between 0.312 and 10 
mg/mL was made. The absorbance was measured at 750 nm in a microplate reader 
(Multiskan GO, Thermo Fischer Scientific®, Northumberland, UK).  
 
3.4.1. GeLC-MS/MS analysis  
 Equal amounts of protein (30 μg) from each concentrated urine sample were 
dissolved (1:2) in loading buffer (0.5 M Tris-HCl pH 6.8, 4% (w/v) SDS, 15% (v/v) 
glycerol, 1 mg/mL bromophenol blue and 20% (v/v) β-mercaptoethanol) and incubated 
at 100°C for 5 minutes. Subsequently, the samples were loaded in a 12.5% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) prepared according to 
Laemmli (141). The gels were run for 45 minutes at 180 V in running buffer (250 mM 
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glycine, 25 mM Tris, pH 8.6 and 0.1% (w/v) SDS). Then, the gels were incubated in 
fixation solution (40% (v/v) methanol and 10% (v/v) glacial acetic acid) for 30 minutes 
and, after being washed with water, gels were stained with Colloidal Coomassie Blue 
G250 and destained with 25% (v/v) methanol until an optimal contrast was achieved. The 
gels were then scanned in the ChemiDoc Imaging System v.2.3.0.07 (Bio-Rad®, 
Hercules, CA, USA). Then, protein bands were cut from the gels (each sample’s gel lane 
was divided into 5 fractions) and placed into eppendorfs for trypsin digestion according 
to Shevchenko et al. (142). Briefly, 100 mM ammonium bicarbonate (NH4HCO3) and 
pure acetonitrile (ACN) was added to each gel fraction, with 30-minute between 
incubations until the gel lose its color. Then, the pieces of gel were reduced with 10 mM 
dithiothreitol (DTT) at 60oC and alkylated with 55 mM iodoacetamide (IAA). After 
incubation with NH4HCO3 and ACN, the supernatant was discarded and gel pieces were 
incubated with trypsin (Pierce, Life Tecnologies, USA) and incubated for 16 hours at 
37°C. The peptides were then extracted and lyophilized in a SpeedVac (Thermo Savant). 
The tryptic peptides were resuspended in 1% (v/v) formic acid (FA) and analyzed 
with a QExactive Orbitrap (Thermo Fisher Scientific, Bremen) through the EASY-spray 
nano ESI source (Thermo Fisher Scientific, Bremen) that was coupled to an Ultimate 
3000 (Dionex, Sunnyvale, CA) high-pressure liquid chromatography (HPLC) system. 
The trap (5 mm × 300 µm internal diameter (ID)) and the EASY-spray analytical (150 
mm × 75 µm) columns used were C18 Pepmap100 (Dionex, LC Packings) having a 
particle size of 3 µm. Peptides were trapped at 30 μL/min in 96 % solvent A (0.1% FA). 
Elution was achieved with the solvent B (0.1 % FA/80 % acetonitrile v/v) at 300 nL/min. 
The 92 min gradient used was as follows: 0–3 min, 96 % solvent A; 3–70 min, 4–25 % 
solvent B; 70–90 min, 25–40 % solvent B; 90–92 min, 90 % solvent B; 90–100 min, 90 
% solvent B; 101-120 min, 96 % solvent A. The mass spectrometer was operated at 1.8 
kV in the data dependent acquisition mode. A MS2 method was used with a FT survey 
scan from 400 to 1600 m/z (resolution 70,000; auto gain control (AGC) target 1E6). The 
10 most intense peaks were subjected to HCD fragmentation (resolution 17,500; AGC 
target 5E4, NCE 28 %, max. injection time 100 ms, dynamic exclusion 35 s). 
Spectra were processed and analyzed using Proteome Discoverer software version 2.2 
(Thermo), with the MS Amanda (version 2.0, University of Applied Sciences Upper 
Austria, Research Institute of Molecular Pathology) and Sequest HT search engines. 
Uniprot (TrEMBL and Swiss-Prot) protein sequence database (version of October 2017) 
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was used for all searches under Homo sapiens. Database search parameters were as 
follows: carbamidomethylation of cysteine, oxidation of methionine, and the allowance 
for up to two missed tryptic cleavages. The peptide mass tolerance was 10 ppm and 
fragment ion mass tolerance was 0.02 Da. To achieve a 1% false discovery rate (FDR), 
the Percolator (version 2.0, Thermo) node was implemented for a decoy database search 
strategy and peptides were filtered for high confidence and a minimum length of 6 amino 
acids, and proteins were filtered for a minimum number of peptide sequences of 1. For 
each protein, minimal number of identified unique peptides was set to two peptides. 
Differences among groups were explored using the free available MetaboAnalyst 
4.0 software (143). To determine the biological processes modulated by cachexia, a 
Cytoscape analysis using the plugins ClueGo+CluePedia (144) was performed. The 
Funrich (145) and STRING (146) were also used to identify the biological processes more 
prevalent in the urine of HNC patients, with and without cachexia, and the cellular origin 
of the proteins identified in the urine.   
 
3.5. Statistical analysis 
Values of the serum parameters are presented as mean ± standard deviation for 
each experimental group. The statistical significance of the differences between groups 
was determined using the unpaired student t-test. The level of significance was set at 5 % 
(p-value < 0.05). These statistical analyses were performed with the GraphPad Prism® 
software for windows (version 7.00). 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
4. RESULTS 
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4.1. Characterization of body wasting phenotype of HNC patients 
 Thirty patients with HNC were included in this study. All patients were male, with 
an average age of 55 years (range 43 to 77 years). In addition, all patients were smokers 
or have previously smoked for several years and presented alcoholic habits. Indeed, only 
one patient never had drinking. Twenty patients reported a body weight loss higher than 
5% in 6 months, 93.33 % of patients presented a BMI lower than 25 and from these, 36.67 
% lower than 18.5, which is indicative of underweight. To accomplish the goal of the 
present study, patients were initially grouped according to body weight loss in the last 6 
months. The comparative analysis of data retrieved from the analysis of circulating 
markers of inflammation and catabolism showed no differences among groups (data not 
shown). Then, HNC patients were grouped according to NRI, which was previously 
demonstrated to be a good marker to identify subjects at risk of malnutrition (147). 
Therefore, from the 30 patients enrolled in the present study, 14 were considered 
cachectic and 16 non-cachectic. No significant age differences were noticed between 
groups. The anthropometric characteristics and clinical information of patients’ groups 
are presented in Table 3. NRI values are presented only for informative purpose since it 
was the criterion used for patients’ grouping. For the determination of NRI, albumin 
values and actual and usual weight information were used, so the statistically significant 
differences observed between groups regarding weight loss and albumin were expected. 
Regarding BMI, this was lower in patients with cachexia (p <0.01). Patients from HNC 
group presented an average BMI of 22, which is an indicator of healthy weight (148). 
A higher frequency of tongue and pharyngeal tumors (33%) were observed in 
patients with no cachexia, whereas pharyngeal tumors (50%) were more frequent in 
cachectic subjects. Concerning the size of the primary tumor (T), a higher percentage 
(70%) of subjects diagnosed with stage T4 was observed. None of the patients from the 
HNC+Cachexia group were diagnosed with stage T1. On the other hand, some patients 
with no signs of cachexia were diagnosed with T1 stage and the percentage of patients 
with stage T4 was 38%. Regarding regional nodal dissemination (N), patients from both 
groups presented a higher frequency of stage N2. In the non-cachexia group, most of the 
subjects were diagnosed with a MUST score of 0. Unlike the observed in this group, in 
HNC+Cachexia group 25% of patients were identified at high risk of malnutrition once 
presented a MUST score of 4. To better characterize the association between weight loss 
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and MUST score, a correlation analysis was performed, and a significant positive 
association was noticed (p<0.0001; Figure 4).  
 
Table 3. Characterization of HNC patients (grouped according to NRI), relative to age, body weight loss, 
BMI, location of tumor, tumor staging and MUST score.  
 Groups 
 HNC HNC+cachexia 
NRI 104.60 ± 3.12 86.60 ± 7.31**** 
Age (years) 57.94 ± 7.05 54.86 ± 5.71 
Body weight loss (Kg) 4.44 ± 3.87 11.29 ± 6.08** 
BMI (Kg/m2) 21.88 ± 3.53 18.33 ± 2.96** 
Location of the tumor, (%)   
Tongue 33.33 25.00 
Pharynx 33.33 50.00 
Larynx 26.66 0.00 
Laryngeal Pharynx 6.67 25.00 
Tumor staging, %   
st
a
g
e 
T
 1 18.75 0.00 
2 0.00 7.69 
3 43.75 23.08 
4 37.50 69.23 
st
a
g
e 
N
 0 31.25 23.00  
1 6.00 0.00 
2 56.25 53.84 
3 6.25 23.07 
MUST score, %   
0 57.14 8.33 
1 7.14 25.00 
2 21.43 33.33 
3 14.29 8.33 
4 0.00 25.00 
Values are expressed as mean ± standard deviation or percentage. ** p<0.01; **** p<0.0001. 
 
In addition to the information presented in Table 3, the information about the 
medication of each patient was made available. Most were analgesics, antihypertensives 
and some psychotropic drugs appear. Apparently, none of the medication seems to play 
a significant role in cancer or cachexia. Only the high frequency of analgesics was noticed 
(data not shown). Although many analgesics cause immunosuppression of innate and 
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humoral defense systems, which the body relies on for the regulation of cancer 
development (149), this did not seem a discriminative factor once it appears in both 
groups. 
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Figure 4. Correlation between weight loss and MUST score.  
 
  
 Concerning biochemical parameters assessed in serum samples, albumin levels 
were significantly distinct between groups (p <0.0001), which was expected since these 
values were used in NRI calculation and, consequently, in patients’ assessment to each 
group. A significant decrease in cholesterol levels (p <0.001) was observed in patients 
with cachexia. For the remaining parameters assessed (glucose, urea, and triglycerides), 
no differences were observed between groups. 
  
 
Table 4. Characterization of the serum biochemical profile of patients with HNC grouped according to 
NRI.  
 Groups 
 HNC HNC+cachexia 
Albumin (g/L) 43.25 ± 0.66 34.21 ± 1.49**** 
Glucose (mmol/L) 5.531 ± 0.203 5.521 ± 0.217 
Urea (mmol/L) 4.34 ± 0.394  3.336 ± 0.291 
Cholesterol (mmol/L) 4.939 ± 0.248 3.653 ± 0.205*** 
Triglycerides (mmol /L) 1.334 ± 0.178 1.114 ± 0.092 
Values are expressed as mean ± standard deviation. *** p<0.001; **** p<0.0001. 
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4.2. Contribution of inflammatory, catabolic and appetite control 
processes to HNC-related body wasting 
 To study the effect of inflammation on the pathogenesis of cachexia in the set of 
HNC, several parameters were assessed in serum samples collected from patients (Figure 
5). The results show that HNC patients with cachexia had significantly higher levels of 
CRP (Figure 5.A) and of the proinflammatory cytokines IL-6 and TNF-α (Figure 5.B and 
5.C, respectively). Despite this pro-inflammatory phenotype, no differences were 
observed in the content of the metalloproteinases MMP2 and MMP9 (Figure 5.D and 
5.E).  
 
Figure 5.  Evaluation of CRP (A), IL-6 (B), TNF-alpha (C) and metalloproteinases 2 (D) and 9 (E) 
circulating levels measured by autoanalyzer (in the case of CRP) or immunoblot. A representative image 
of the obtained blots is shown above the graph. The values (mean ± SD) of the CRP are expressed in mg/L 
and of the other parameters in arbitrary units of optical density (OD). * p <0.05; ** p <0.01. 
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 Figure 6 shows the results obtained from the analysis of catabolic and appetite 
control molecular markers, represented by myostatin (Mstn; Figure 6.A) and ghrelin 
(Figure 6.B). HNC patients with cachexia presented significantly elevated levels of the 
myokine Mstn, which may be suggestive of muscle mass loss. Regarding ghrelin, no 
differences of its circulating levels were observed between groups, suggesting that there 
were no changes in appetite regulation. However, a negative correlation between ghrelin 
and CRP was observed (p=0.0056). Data suggest that inflammation is related to decreased 
appetite (Figure 7).  
 
Figure 6. Levels of the catabolic marker, Mstn (A), and appetite control, ghrelin (B), measured by 
immunoblot analysis of serum samples. A representative image of the obtained blots is shown above the 
graph. The values (mean ± SD) are expressed in arbitrary units of optical density (OD). ** p <0.01. 
 
 To better explore this result, patients were tentatively grouped according to body 
weight loss and CRP values. For patients with body weight loss higher than 5% in less 
than 6 months and high circulating levels of CRP, significantly lower values of ghrelin 
were noticed compared to patients with no body weight loss and normal values of CRP 
(Figure S1). 
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Figure 7. Correlation between ghrelin and CRP circulating levels.  
 
 
4.3. Characterization of urine proteome profile among HNC patients` 
groups. 
 The analysis of urine proteome from ten HNC patients, with and without cachexia 
according to NRI values, allowed the identification of a total of 520 distinct proteins. 
According to FunRich software (145) most of these proteins belong to “metabolism”, 
“immune response” and “cell growth and maintenance” biological processes. Regarding 
the cellular component, most of these proteins are derived from exosomes and of 
extracellular origin.  
 The comparative analysis between groups using MetaboAnalyst software 
(www.metaboanalyst.ca/)  highlight a clear urine proteome separation between groups, 
except for one patient from the HNC+Cachexia group (Figure 8). In fact, a closer analysis 
of serum markers and clinical data of this patient showed low levels of CRP levels (5.4 
mg/L) compared to the other cachectic patients, despite a NRI lower than 97.5, and a 
normal BMI value. 
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Figure 8. Principal Component Analysis plot of the proteins present in the urine from the two groups of 
patients. 
 
 
Looking to the proteins present in significant distinct amounts between groups, 18 
proteins were identified (Table 5). Eleven proteins were present in significant higher (pink 
table lines) levels in the urine of cachectic patients whereas seven were in significant 
lower (blue table lines) amounts.  
The analysis of the biological processes with the ClueGo+CluePedia plugins from 
Cytoscape software considering the proteins present in significant higher levels in 
HNC+Cachexia group highlighted the contribution of “ROS metabolism” and the 
“regulation of leukocytes metabolism” whereas the lower abundant proteins belong to 
“hydrogen peroxide catabolism process”. Among the proteins found in higher amounts in 
the urine of cachectic patients are CRP, which highlight the contribution of inflammation 
to cachexia pathogenesis, further supporting data from serum analysis. The enzyme 
argininosuccinate synthase was previously associated to HNC (150). Also, cornulin, 
small proline-rich protein 3 and cystatin-B have been previously associated with HNC 
(151,152). Regarding cornulin, loss of its expression seems to be associated with the 
development of local relapse (151). Small proline-rich protein 3 was associated with 
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increased sensitivity of cancer cells in response to DNA damage-induced apoptosis (153). 
However, no prior association of these proteins to cachexia pathogenesis was found. The 
C4b-binding protein alpha chain was previously associated to the positive regulation of 
the catabolic process (154), supporting its putative involvement in cachexia. 
Carboxymethylenebutenolidase homolog was involved to in the differentiation of 
myoblasts, being implicated in the differentiation and responsiveness of myoblasts to 
TNF-α (155). 
 45 
 
Table 5. Comparative quantitative analysis of urine proteome between groups. The proteins at the bottom of the table (pink) are the ones present in higher amounts in the urine 
of HNC patients with cachexia. The proteins at the top of the table (blue) are proteins present in higher amounts in the urine of non-cachectic HNC patients. 
Accession 
number 
(Uniprot) 
Name Coverage [%] Peptides 
MW 
[kDa] 
pI 
Abundance Ratio: 
(HNC+Cach) / 
(HNC) 
P-Value: 
(HNC+Cach) / 
(HNC) 
P14780 Matrix metalloproteinase-9 4 2 78.4 6.06 0.01 3.02E-16 
P02042 Hemoglobin subunit delta 45 7 16 8.05 0.01 3.02E-16 
P55291 Cadherin-15 16 8 88.9 4.98 0.179 0.001762 
Q8N307 Mucin-20 26 2 71.9 5.07 0.198 0.004114 
Q66K79 Isoform 2 of Carboxypeptidase Z 3 2 72.5 8.09 0.243 0.020615 
Q6UX06 Olfactomedin-4 40 16 57.2 5.69 0.25 0.02573 
P05164 Isoform H7 of Myeloperoxidase 6 4 87.2 9.07 0.267 0.040073 
Q9UBG3 Cornulin 20 4 53.5 6.1 4.299 0.040069 
Q96DG6 Carboxymethylenebutenolidase homolog 13 2 28 7.18 4.604 0.02434 
P16083 Ribosyldihydronicotinamide dehydrogenase [quinone] 13 2 25.9 6.29 4.758 0.019244 
P00966 Argininosuccinate synthase 5 2 46.5 8.02 4.799 0.018177 
P04003 C4b-binding protein alpha chain 6 3 67 7.3 5.087 0.011475 
P02741 C-reactive protein 9 2 25 5.63 5.153 0.010451 
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 10 6 106.4 6.86 6.03 0.002888 
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 3 3 99.8 5.74 8.422 0.000132 
Q6UWR7 
Ectonucleotide pyrophosphatase/phosphodiesterase family 
member 6 [OS=Homo sapiens] 
8 3 50.2 7.99 100 3.02E-16 
P04080 Cystatin-B [OS=Homo sapiens] 37 2 11.1 7.56 100 3.02E-16 
Q9UBC9 Small proline-rich protein 3 [OS=Homo sapiens] 18 2 18.1 8.57 100 3.02E-16 
 
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
5. DISCUSSION 
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The high rates of morbidity and mortality in patients with HNC are closely associated 
with critical weight loss, a common feature in these patients (156). Weight loss is greater 
and has a higher incidence in HNC patients compared to other cancer patients because, at 
least in part, to the difficulty in swallowing presented by these patients (157). Smoking 
and drinking habits, the most common etiological factors associated to the development 
of HNC, has also been associated to malnutrition (157). Indeed, Martin Villares et al. 
(158) showed that the risk of malnutrition increased with the amount of alcohol 
consumed. One of the hypotheses raised to explain this association is the thiamine 
deficiency evidenced by patients with alcohol dependence, which seems to result in poor 
oral absorption (159). However, several studies associate HNC with cachexia (42,160), a 
syndrome characterized by muscle loss not reverted by parental nutrition (41). The 
clinical management of cachexia is complex and rarely recognized or assessed (161). 
Indeed, more than 80 clinical trials have been conducted to assess the putative anti-cancer 
cachexia effect of proposed therapeutic strategies (www.clinicaltrials.go) but no 
successful results were reported. This may be justified, at least in part, by the misdiagnosis 
of cachexia in the set of HNC. To overcome this gap, we applied a proteomic strategy to 
characterize body fluids collected from HNC patients with and without a wasting 
phenotype. The biggest challenge that we faced was how to group patients with 
(HNC+Cachexia group) and without cachexia (HNC group). The Nutritional Risk Index 
(NRI) was the index chosen because it is highly sensitive when compared to other 
nutritional assessments. In the investigation of the ability to detect conditions such as 
sarcopenia, myosteatosis, pre-cachexia, and cancer cachexia, NRI presented the better 
accuracy (about 74.7%) in identifying patients with at least one of these conditions, when 
compared to other screening tools (e.g. MST, Malnutrition Screening Tool; MUST, 
Malnutrition Universal Screening Tool) (162). 
 
Once established the experimental groups, we performed a targeted proteomic 
analysis of serum samples. Several protein targets were selected, specifically 
inflammatory, catabolic and appetite control markers. One of the main features of 
cachexia is inflammation (43). The presence of an inflammatory state is one of the points 
that distinguishes cachexia from other syndromes such as sarcopenia (52,163); however, 
inflammation is always present in HNC, even if not at very high levels (164). So, one of 
the focus of this study was the link between inflammation and body weight loss. Although 
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non-specific, CRP is a sensitive marker of inflammation. Its synthesis by hepatocytes is 
induced by proinflammatory cytokines, mainly IL-6. Our results show a significant 
increase of serum CRP and IL-6 in patients with cachexia (Figure 5). The persistence of 
an inflammatory state results in the continuous production of this acute phase protein, 
promoting the reprioritization of amino acid metabolism in peripheral tissues, especially 
muscles, towards the liver. Therefore, muscle catabolism is expected to occur (165). The 
increase of circulating CRP levels in cachectic patients was paralleled by the increase of 
IL-6 (Figure 5), which is known to promote the liver synthesis of CRP (165).  
Besides IL-6, circulating TNF-α levels were previously associated with HNC 
(59,84). Our results evidenced increased levels of these cytokines in the group of patients 
with cachexia (Figure 5), reinforcing the contribution of inflammation to the wasting 
phenotype. Moreover, higher levels of inflammatory markers have been associated with 
lower strength and muscle mass (166). This appears to be explained by the fact that IL-6 
activates the JAK/STAT3 signaling pathway in skeletal muscle, leading to the UPP 
activation and inhibition of the PI3K/Akt/mTOR pathway (64). On the other hand, TNF-
α activates the NF-B and p38 MAPK pathways, both of which induce the upregulation 
of the major E3 ligases (MuRF1 and atrogin) that mediate muscle mass loss and protein 
synthesis inhibition (113). 
The contribution of muscle catabolism to the HNC-related wasting phenotype was 
evaluated through the analysis of circulating myostatin. Since myostatin is secreted and 
expressed mainly by the skeletal muscle, its main function is the negative regulation of 
muscle mass (blocking myoblast proliferation and suppression of satellite cell activation) 
(167). In fact, studies demonstrate that myostatin is implicated in various diseases 
involving muscle mass loss (168,169). Data obtained highlight a significant increase of 
this protein in the serum from patients with cachexia (Figure 6). A negative correlation 
has already been made between elevated myostatin serum levels and skeletal muscle mass 
(170). Therefore, this result suggests the involvement of muscle mass loss in the 
pathogenesis of cachexia. The role of myostatin in the regulation of muscle mass involves 
the activation of activin type I and II receptors (125). Thus, these receptors may be seen 
as putative therapeutic targets. In fact, BY338 (131) and REGN10 (132), two monoclonal 
antibodies, were shown to inhibit the activin type II receptor with the consequent 
preservation of muscle mass; however, studies were only done on pre-clinical models. 
 51 
 
Appetite dysregulation has been suggested to contribute to body weight loss in 
cancer (171). Ghrelin, mainly produced by the entero-endocrine cells of the stomach 
(125), was the marker selected in our study for the analysis of the contribution of appetite 
regulation to cachexia pathogenesis. This hormone binds to the GH receptor and 
stimulates appetite via neuropeptide Y activation in the hypothalamus (125). No 
significant variations of ghrelin levels were observed among the studied groups (Figure 
6), which suggests that appetite control is not a good therapeutic target for the 
management of HNC cachexia. However, a significant negative correlation was observed 
between ghrelin and CRP (Figure 7). Thus, patients with high levels of CRP (above 30 
mg/L) may benefit from the therapeutic use of ghrelin analogs. Indeed, there are clinical 
trials reporting positive results for the use of ghrelin analogs in the regulation of body 
composition and weight gain. Ghrelin analogs have been preferred to ghrelin because the 
use of the hormone was associated to many severe adverse events, such as acute 
myocardial infarction (172). Anamorelin is an analog of ghrelin used in several studies 
and despite the good results in terms of nutritional status and increase in lean mass, the 
results related to muscle function are contradictory (173,174).  
CRP and ghrelin results reinforce the importance of the criteria used to group 
patients on data variation of selected parameters. Indeed, despite being considered 
cachectic according to the NRI, some of the patients presented low levels of 
inflammation, which is not in agreement with the previously supposed about the 
contribution of inflammation to cachexia. These results raised some curiosity and interest 
in the study of a possible third group of patients (Figure S1) with characteristics like 
weight loss, but without inflammation. Using this criterion, it is clear the association 
between inflammation and appetite dysregulation. Thus, efforts should continue to be 
made to promote a better diagnosis of cachexia and, consequently, improve the selection 
of therapeutic approaches.  
 
In order to explore the diagnosis value of urine in cancer cachexia and to identify 
novel markers of this syndrome, we applied a high throughput MS-based approach to 
characterize the urine proteome from HNC patients with and without cachexia (according 
to the NRI score). Compared to blood-derived fluids, urine has several advantages such 
as its non-invasively collection in unrestricted amounts. In addition, urine proteome is not 
dominated by highly abundant proteins. Indeed, serum proteome is dominated by 22 
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(highly abundant) proteins that make up 99% of the total protein mass, with half of this 
mass represented by albumin (175). Urine proteome is less complex, containing 
approximately 2000 proteins against more than 10000 of the plasma (176).  
Using a GeLC-MS/MS approach we identified 520 distinct proteins (each with 2 
peptides, FDR lower than 1%). Within the set of the identified proteins are commonly 
found urinary proteins such as uromodulin (177), immunoglobulins (178) and osteopontin 
(179). In overall, most of the identified proteins belong to the biological processes 
"metabolism", "immune response" and "cell growth and maintenance”. The “immune 
response” and “metabolism” draw attention within the scope of this work since the 
progression of cancer and cachexia depends on the immune response. The metabolism of 
neoplastic cells may have contributed to the urine proteome of HNC patients. Altered 
metabolic activity related to lipolysis, the TCA cycle, and amino acid catabolism was 
previously reported in the set of HNC (180). HNC tumors affect the metabolism of their 
hosts in such a way that it can most often result in cachexia (181). At the same time, the 
cachexia itself affects much of the metabolism of the human body (113).  
The comparative analysis of urine proteome between patients with and without 
cachexia showed 18 proteins in significant different amounts. The analysis of the 
biological processes involving these proteins highlighted "ROS metabolism" and 
"regulation of leukocyte metabolism". CRP was present in higher amounts in the urine of 
cachectic patients confirming the results obtained in the serum analysis. C4b binding 
protein alpha chain, another protein found in greater amounts in the urine of cachectic 
patients, is also an acute phase protein (182) that belongs to the complement system (183). 
These results also reinforce the contribution of inflammation to the development of 
cachexia. Other proteins identified in higher amounts in the urine of cachectic patients 
were previously associated with HNC, including the enzyme argininosuccinate synthase 
(150), cornulin, small proline-rich protein 3 and cystatin B (151,152). Increased urinary 
and serum levels of argininosuccinate synthase were reported to be associated with 
inflammation (184). Cornulin and the small proline-rich protein 3 make part of the 
protective barrier of the mucosa and the skin (151). Previous studies showed a low 
expression of these proteins in the tumor tissue from HNC patients (151,152), possibly 
justifying the increased content observed in the urine of patients at advanced stage of the 
disease. However, the negative regulation of cornulin has been reported in several types 
of cancer and associated with advanced clinical stages, making difficult to comprehend 
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its increase in the urine of HNC patients with cachexia. Cystatin-B, a cathepsin-B 
inhibitor, was also found to be diminished in HNSCC (tissue samples) (152), unlike the 
reported in the set of bladder cancer (185). To the best of our knowledge, 
ribosyldihydronicotinamide dehydrogenase, a protein that confers protection against 
oxidative stress and carcinogenesis (186), was not previously associated to HNC neither 
to cachexia. Future studies will be important to increase the number of urine samples 
analyzed and to validate these putative HNC cachexia biomarkers such as CRP, C4-
binding protein alpha chain and argininosuccinate synthase. 
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 Cachexia is a common problem among patients with HNC; however, this 
syndrome is often misdiagnosed despite its negative impact on disease outcomes. To add 
new insights on this issue, targeted and non-targeted proteomics analysis of body fluids 
from 30 HNC patients was performed and the results obtained were correlated with 
clinical information. Data integration allowed us to take the following conclusions: 
i) The diagnosis of cachexia based on body weight loss higher than 5% in less 
than 6 months does not allow the discrimination of HNC patients with 
laboratory biochemical parameters. NRI seems to be a better assessment tool 
of cachexia in the set of HNC;  
ii)  Cachexia (based on an NRI lower than 97.5) is associated to advanced stages 
of disease, high degree of inflammation, given by increased levels of CRP, 
TNF-α, and IL-6, and muscle catabolism, which is related to high levels of 
circulating myostatin;  
iii) The negative correlation observed between circulating levels of ghrelin and 
CRP suggests that patients with CRP levels higher than 30 mg/dL may benefit 
from therapy with ghrelin agonists;  
iv) Urine proteomics confirmed the diagnosis value of this body fluid since a clear 
separation of proteome profile was observed among HNC patients with and 
without cachexia; 
v) Eleven proteins were found in higher levels in the urine of cachectic patients, 
being of notice C4 binding protein alpha chain, CRP and argininosuccinate 
synthase, which emphasizes the contribution of inflammation to HNC 
cachexia pathogenesis.  
 Future studies will be important to increase the number of samples analyzed and 
to validate the putative biomarkers identified, envisioning the improvement of cachexia 
diagnosis in the set of HNC and, eventually, in other cancer types.  We believe that more 
than one biomarker, a multimarker panel combining several protein targets will better 
approach the cachexia diagnosis, improving the management of this syndrome and, 
consequently, disease prognosis. 
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Figure S1. Levels of expression of the appetite control parameter, ghrelin (A), measured by immunoblot, 
of patients with HNC, without weight loss and without inflammation (HNC), with weight loss and 
inflammation (HNC+BWL+INF) and with weight loss and without inflammation (HNC+BWL-INF). A 
representative immunoblot is presented in (B). The values (mean ± SD) are expressed in arbitrary units of 
optical density (OD). * p <0.05. 
 
Table S1.  Reference values of the serum parameters provided by the IPO. 
Laboratory parameter Reference values  
Albumin  38-53 (g/L) 
Glucose 4.2-6.4 (mmol/L) 
Urea 1.6-8.3 (mmol/L) 
Cholesterol <5.18 (mmol/L) 
Triglycerides 0.5-1.71 (mmol/L) 
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Table S2. List of proteins identified in the GeLC-MS/MS analysis of urine from 10 HNC patients (520 different proteins). 
Accession Description 
Coverage 
[%] 
Peptides 
MW 
[kDa] 
calc. 
pI 
Abundance Ratio: 
(Sample) / 
(Control) 
P-Value: 
(Sample) / 
(Control) 
Q6UWR7 
Ectonucleotide pyrophosphatase/phosphodiesterase family member 6 
[OS=Homo sapiens] 
8 3 50.2 7.99 100 3.02E-16 
P04080 Cystatin-B [OS=Homo sapiens] 37 2 11.1 7.56 100 3.02E-16 
P14780 Matrix metalloproteinase-9 [OS=Homo sapiens] 4 2 78.4 6.06 0,01 3.02E-16 
Q9UBC9 Small proline-rich protein 3 [OS=Homo sapiens] 18 2 18.1 8,57 100 3.02E-16 
P02042 Hemoglobin subunit delta [OS=Homo sapiens] 45 7 16 8.05 0.01 3.02E-16 
Q06033-1 Inter-alpha-trypsin inhibitor heavy chain H3 [OS=Homo sapiens] 3 3 99.8 5.74 8.422 0.000132 
P55291 Cadherin-15 [OS=Homo sapiens] 16 8 88.9 4.98 0.179 0.001762 
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 [OS=Homo sapiens] 10 6 106.4 6.86 6.03 0.002888 
Q8N307 Mucin-20 [OS=Homo sapiens] 26 2 71.9 5.07 0.198 0.004114 
P02741-1 C-reactive protein [OS=Homo sapiens] 9 2 25 5.63 5.153 0.010451 
P04003 C4b-binding protein alpha chain [OS=Homo sapiens] 6 3 67 7.3 5.087 0.011475 
P00966 Argininosuccinate synthase [OS=Homo sapiens] 5 2 46.5 8.02 4.799 0.018177 
P16083 
Ribosyldihydronicotinamide dehydrogenase [quinone] [OS=Homo 
sapiens] 
13 2 25.9 6.29 4.758 0.019244 
Q66K79-2 Isoform 2 of Carboxypeptidase Z [OS=Homo sapiens] 3 2 72.5 8.09 0.243 0.020615 
Q96DG6 Carboxymethylenebutenolidase homolog [OS=Homo sapiens] 13 2 28 7.18 4.604 0.02434 
Q6UX06 Olfactomedin-4 [OS=Homo sapiens] 40 16 57.2 5.69 0.25 0.02573 
Q9UBG3 Cornulin [OS=Homo sapiens] 20 4 53.5 6.1 4.299 0.040069 
P05164-3 Isoform H7 of Myeloperoxidase [OS=Homo sapiens] 6 4 87.2 9.07 0.267 0.040073 
P48735 Isocitrate dehydrogenase [NADP], mitochondrial [OS=Homo sapiens] 8 3 50.9 8.69 3.643 0.085729 
Q95604 
HLA class I histocompatibility antigen, Cw-17 alpha chain 
[OS=Homo sapiens] 
10 2 41.2 6.8 0.314 0.85729 
P05546 Heparin cofactor 2 [OS=Homo sapiens] 5 3 57 6.9 3.587 0.090394 
Q9HBJ8 Collectrin [OS=Homo sapiens] 13 2 25.2 5.63 3.574 0.091971 
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P0DOX3 immunoglobulin delta heavy chain [OS=Homo sapiens] 6 2 56.2 8.02 3.535 0.098044 
P0C0L4-1 Complement C4-A [OS=Homo sapiens] 32 39 192.7 7.08 0.35 0.148373 
P07900-2 Isoform 2 of Heat shock protein HSP 90-alpha [OS=Homo sapiens] 7 5 98.1 5.16 3.27 0.148373 
P52823 Stanniocalcin-1 [OS=Homo sapiens] 13 2 27.6 7.99 3.222 0.159845 
P02792 Ferritin light chain [OS=Homo sapiens] 18 3 20 5.78 0.356 0.161447 
Q9BTY2 Plasma alpha-L-fucosidase [OS=Homo sapiens] 6 2 54 6.25 3.144 0.18097 
P08571 Monocyte differentiation antigen CD14 [OS=Homo sapiens] 43 13 40.1 6.23 0.368 0.191799 
Q6UXB8-1 Peptidase inhibitor 16 [OS=Homo sapiens] 22 7 49.4 5.39 0.37 0.194171 
P07686 Beta-hexosaminidase subunit beta [OS=Homo sapiens] 22 10 63.1 6.76 2.927 0.250525 
P13671 Complement component c6 [OS=Homo sapiens] 4 2 104.7 6.76 2.887 0.264851 
P25311 Zinc-alpha-2-glycoprotein [OS=Homo sapiens] 58 22 34.2 6.05 0.403 0.289474 
P05062 fructose-bisphosphate aldolase B [OS=Homo sapiens] 39 10 39.4 7.87 2.835 0.289474 
P09668 Pro-cathepsin H [OS=Homo sapiens] 12 4 37.4 8.07 2.833 0.289474 
P30039 
Phenazine biosynthesis-like domain-containing protein [OS=Homo 
sapiens] 
10 2 31.8 6.52 2.828 0.289474 
P04196 Histidine-rich glycoprotein [OS=Homo sapiens] 11 4 59.5 7.5 2.821 0.291738 
P12273 Prolactin-inducible protein [OS=Homo sapiens] 33 5 16.6 8.05 0.408 0.302855 
P80188 Neutrophil gelatinase-associated lipocalin [OS=Homo sapiens] 46 7 22.6 8.91 0.413 0.315967 
P12882 Myosin-1 [OS=Homo sapiens] 5 6 223 5.74 0.416 0.315967 
P02760 Protein AMBP [OS=Homo sapiens] 52 19 39 6.25 0.423 0.345973 
Q9Y653 Adhesion G-protein coupled receptor G1 [OS=Homo sapiens] 3 2 77.7 8.48 0.429 0.357041 
P20711 aromatic-L-amino-acid decarboxylase [OS=Homo sapiens] 5 2 53.9 7.2 2.648 0.360998 
Q04756 Hepatocyte growtH factor activator [OS=Homo sapiens] 3 2 70.6 7.24 0.437 0.385481 
P02765 Alpha-2-HS-glycoprotein [OS=Homo sapiens] 40 10 39.3 5.72 0.442 0.399838 
Q96PD5-2 
Isoform 2 of N-acetylmuramoyl-L-alanine amidase [OS=Homo 
sapiens] 
23 10 68 7.68 0.447 0.419337 
P04792 Heat shock protein beta-1 [OS=Homo sapiens] 21 3 22.8 6.4 2.542 0.426764 
P19961 Alpha-amylase 2B [OS=Homo sapiens] 50 17 57.7 7.09 0.453 0.434403 
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P05543 thyroxine-binding globulin [OS=Homo sapiens] 34 11 46.3 6.3 0.463 0.475057 
P05787-2 Isoform 2 of Keratin, type II cytoskeletal 8 [OS=Homo sapiens] 7 3 56.6 5.43 2.462 0.479089 
P02743 Serum amyloid P-component [OS=Homo sapiens] 26 6 25.4 6.54 0.471 0.510173 
P34896-1 Serine hydroxymethyltransferase, cytosolic [OS=Homo sapiens] 9 3 53 7.71 2.421 0.510173 
P51884 Lumican [OS=Homo sapiens] 14 3 38.4 6.61 0.472 0.510173 
Q9Y2S2-1 Lambda-crystallin homolog [OS=Homo sapiens] 11 3 35.4 6.18 2.395 0.532624 
P04075 fructose-bisphosphate aldolase A [OS=Homo sapiens] 13 3 39.4 8.09 2.356 0.544506 
Q9H0W9 Ester hydrolase C11orf54 [OS=Homo sapiens] 13 3 35.1 6.7 2.361 0.544506 
O00533-2 
Isoform 2 of Neural cell adhesion molecule L1-like protein 
[OS=Homo sapiens] 
2 2 136.6 5.8 2.356 0.544506 
O94919 endonuclease domain-containing 1 protein [OS=Homo sapiens] 34 11 55 5.71 0.488 0.557938 
P02788 Lactotransferrin [OS=Homo sapiens] 56 28 78.1 8.12 0.489 0.55876 
Q9Y6R7 IgGFc-binding protein [OS=Homo sapiens] 6 12 571.6 5.34 0.494 0.57726 
P0DJD8 Pepsin A-3 [OS=Homo sapiens] 9 4 42 4.41 0.495 0.578242 
P52565 rho GDP-dissociation inhibitor 1 [OS=Homo sapiens] 16 2 23.2 5.11 2.305 0.578242 
P50995 annexin A11 [OS=Homo sapiens] 12 5 54.4 7.65 0.497 0.579995 
P09467 Fructose-1,6-bisphosphatase 1 [OS=Homo sapiens] 33 7 36.8 6.99 2.275 0.607632 
P06702 Protein S100-A9 [OS=Homo sapiens] 25 2 13.2 6.13 0.509 0.640344 
P05451 Lithostathine-1-alpha [OS=Homo sapiens] 48 7 18.7 5.94 0.512 0.643973 
P68032 Actin, alpha cardiac muscle 1 [OS=Homo sapiens] 35 9 42 5.39 2.236 0.643973 
P00749 Urokinase-type plasminogen activator [OS=Homo sapiens] 42 13 48.5 8.41 0.516 0.647982 
Q9BRK3-2 
Isoform 2 of Matrix remodeling-associated protein 8 [OS=Homo 
sapiens] 
23 9 49.6 6.92 0.522 0.657939 
P69905 Hemoglobin subunit alpha [OS=Homo sapiens] 58 6 15.2 8.68 0.519 0.657939 
Q14767 
Latent-transforming growth factor beta-binding protein 2 [OS=Homo 
sapiens] 
2 3 194.9 5.19 0.522 0.657939 
Q9BUT1-1 3-hydroxybutyrate dehydrogenase type 2 [OS=Homo sapiens] 10 2 26.7 7.65 2.195 0.657939 
P39059 Collagen alpha-1(XV) chain [OS=Homo sapiens] 6 6 141.6 5 0.527 0.673338 
Q8WVN6 Secreted and transmembrane protein 1 [OS=Homo sapiens] 22 4 27 7.43 0.527 0.673338 
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P08603-1 complement factor H [OS=Homo sapiens] 6 6 139 6.61 2.15 0.6826 
Q15113 Procollagen C-endopeptidase enhancer 1 [OS=Homo sapiens] 13 4 47.9 7.43 0.534 0.694995 
P07339 Cathepsin D [OS=Homo sapiens] 48 15 44.5 6.54 2.12 0.715767 
P26038 Moesin [OS=Homo sapiens] 15 8 67.8 6.4 2.093 0.746021 
P01024 Complement C3 [OS=Homo sapiens] 40 51 187 6.4 2.092 0.746284 
Q15274 
nicotinate-nucleotide pyrophosphorylase [carboxylating] [OS=Homo 
sapiens] 
9 2 30.8 6.21 2.087 0.749057 
Q9UKU9 angiopoietin-related protein 2 [OS=Homo sapiens] 19 8 57.1 7.53 0.55 0.753713 
P55287-1 Cadherin-11 [OS=Homo sapiens] 10 5 87.9 4.91 0.551 0.753713 
P60709 Actin, cytoplasmic 1 [OS=Homo sapiens] 42 11 41.7 5.48 2.064 0.765022 
P06396 Gelsolin [OS=Homo sapiens] 28 11 85.6 6.28 0.559 0.776505 
Q93088 Betaine--homocysteine S-methyltransferase 1 [OS=Homo sapiens] 40 10 45 7.03 2.041 0.776505 
P08185 corticosteroid-binding globulin [OS=Homo sapiens] 26 8 45.1 6.04 0.56 0.776505 
P04180 phosphatidylcholine-sterol acyltransferase [OS=Homo sapiens] 13 5 49.5 6.11 0.558 0.776505 
P02675 Fibrinogen beta chain [OS=Homo sapiens] 45 16 55.9 8.27 2.029 0.788034 
O75882-1 Attractin [OS=Homo sapiens] 13 13 158.4 7.31 0.567 0.7929 
P10643 Complement component C7 [OS=Homo sapiens] 12 7 93.5 6.48 2.002 0.80048 
P62258-1 14-3-3 protein epsilon [OS=Homo sapiens] 17 4 29.2 4.74 1.994 0.811171 
Q13510-2 Isoform 2 of Acid ceramidase [OS=Homo sapiens] 36 12 46.5 7.85 1,972 0.82223 
Q96KP4 cytosolic non-specific dipeptidase [OS=Homo sapiens] 35 11 52.8 5.97 1.932 0.82223 
O00468-3 Isoform 3 of Agrin [OS=Homo sapiens] 6 7 215.2 6.51 0.585 0.82223 
P24855 Deoxyribonuclease-1 [OS=Homo sapiens] 43 6 31.4 4.91 0,596 0.82223 
Q12794-1 Hyaluronidase-1 [OS=Homo sapiens] 18 5 48.3 6.77 0.592 0.82223 
P08519 apolipoprotein(a) [OS=Homo sapiens] 19 4 501 5.88 0.588 0.82223 
P29508 Serpin B3 [OS=Homo sapiens] 14 4 44.5 6.81 0.582 0.82223 
P0DMV8 heat shock 70 kDa protein 1A [OS=Homo sapiens] 9 4 70 5.66 1.973 0.82223 
P59665 Neutrophil defensin 1 [OS=Homo sapiens] 19 2 10.2 6.99 0.578 0.82223 
Q99969 Retinoic acid receptor responder protein 2 [OS=Homo sapiens] 14 2 18.6 9.09 0.581 0.82223 
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O14745 
Na(+)/H(+) exchange regulatory cofactor NHE-RF1 [OS=Homo 
sapiens] 
8 2 38.8 5.77 1.939 0.82223 
P58499-2 Isoform A of Protein FAM3B [OS=Homo sapiens] 9 2 30.4 9 0.592 0.82223 
P01009-1 alpha-1-antitrypsin [OS=Homo sapiens] 56 24 46.7 5.59 1.898 0.837154 
P04746 Pancreatic alpha-amylase [OS=Homo sapiens] 59 19 57.7 7.05 0.602 0.837154 
P23470 
Receptor-type tyrosine-protein phosphatase gamma [OS=Homo 
sapiens] 
3 4 161.9 642 0.601 0.837154 
P04216 Thy-1 membrane glycoprotein [OS=Homo sapiens] 24 3 17.9 8.73 0.602 0.837154 
P06732 Creatine kinase M-type [OS=Homo sapiens] 18 5 43.1 7.25 0.608 0.848378 
Q9HCU0 endosialin [OS=Homo sapiens] 15 7 80.8 5.35 0.609 0.852323 
P51688 N-sulphoglucosamine sulphohydrolase [OS=Homo sapiens] 28 10 56.7 6.95 1.865 0.869906 
P01602 Immunoglobulin kappa variable 1-5 [OS=Homo sapiens] 29 2 12.8 8.28 0.615 0.875985 
P04083 annexin A1 [OS=Homo sapiens] 36 9 38.7 7.02 1.853 0.881084 
Q9BYF1 angiotensin-converting enzyme 2 [OS=Homo sapiens] 3 2 92.4 5.54 1.847 0.881084 
P26842 CD27 antigen [OS=Homo sapiens] 16 2 29.1 7.64 1.853 0.881084 
P68363 Tubulin alpha-1B chain [OS=Homo sapiens] 20 6 50.1 5.06 1.826 0.88414 
P01861 Immunoglobulin heavy constant gamma 4 [OS=Homo sapiens] 49 10 35.9 736 1.836 0.88414 
Q9H6X2 Anthrax toxin receptor 1 [OS=Homo sapiens] 8 4 62.7 7.61 0.626 0.88414 
Q9HCN6-3 Isoform 3 of Platelet glycoprotein VI [OS=Homo sapiens] 6 3 67.4 879 0.624 0.88414 
O43653 prostate stem cell antigen [OS=Homo sapiens] 23 3 12.9 5.29 0.624 0.88414 
P27105 erythrocyte band 7 integral membrane protein [OS=Homo sapiens] 11 2 31.7 7.88 1.822 0.88912 
P14550 alcohol dehydrogenase [NADP(+)] [OS=Homo sapiens] 16 3 36.6 6.79 1.811 0.898654 
P12277 Creatine kinase B-type [OS=Homo sapiens] 10 3 42.6 5.59 1.809 0.900497 
P80748 Immunoglobulin lambda variable 3-21 [OS=Homo sapiens] 39 2 12.4 5.29 1.804 0.908235 
P07288-1 Prostate-specific antigen [OS=Homo sapiens] 73 10 28.7 7.68 0.642 0.912559 
O00187-1 Mannan-binding lectin serine protease 2 [OS=Homo sapiens] 13 10 75.7 5.63 0.637 0.912559 
P08582-1 Melanotransferrin [OS=Homo sapiens] 17 9 80.2 5.94 0.644 0.912559 
Q9UHL4 Dipeptidyl peptidase 2 [OS=Homo sapiens] 17 7 54.3 6.32 1.77 0.912559 
 85 
 
P05452 Tetranectin [OS=Homo sapiens] 35 6 22.5 5.67 0.635 0.912559 
P13473-3 
Isoform LAMP-2C of Lysosome-associated membrane glycoprotein 2 
[OS=Homo sapiens] 
7 3 45.1 5.91 1.778 0.912559 
P98095-2 Isoform 2 of Fibulin-2 [OS=Homo sapiens] 3 3 131.8 4.86 0.638 0.912559 
Q15485-1 Ficolin-2 [OS=Homo sapiens] 15 3 34 6.77 0.645 0.912559 
P00338-3 Isoform 3 of L-lactate dehydrogenase A chain [OS=Homo sapiens] 9 3 39.8 8.43 1.772 0.912559 
P52758 2-iminobutanoate/2-iminopropanoate deaminase [OS=Homo sapiens] 34 3 14.5 8.68 1.765 0.919652 
P15121 aldose reductase [OS=Homo sapiens] 8 2 35.8 6.98 0.651 0.931572 
P41222 Prostaglandin-H2 D-isomerase [OS=Homo sapiens] 35 4 21 7.8 0.651 0.931674 
P07858 Cathepsin B [OS=Homo sapiens] 25 6 37.8 6.3 1.752 0.931795 
Q16769 glutaminyl-peptide cyclotransferase [OS=Homo sapiens] 43 9 40.9 6.61 0.661 0.931917 
P02766 Transthyretin [OS=Homo sapiens] 65 7 15.9 5.76 0.661 0.931917 
Q02818 Nucleobindin-1 [OS=Homo sapiens] 12 4 53.8 5.25 1.724 0.931917 
P04066 tissue alpha-L-fucosidase [OS=Homo sapiens] 8 3 53.7 6.84 1.722 0.931917 
A0A0B4J1Y8 immunoglobulin lambda variable 9-49 [OS=Homo sapiens] 16 2 13 7.28 1.746 0.931917 
P13797 Plastin-3 [OS=Homo sapiens] 4 2 70.8 5.6 1.718 0.931917 
P10451-1 Osteopontin [OS=Homo sapiens] 49 12 35.4 4.58 1.724 0.931917 
Q13509 tubulin beta-3 chain [OS=Homo sapiens] 7 2 50.4 4.93 1.717 0.931917 
Q12860 Contactin-1 [OS=Homo sapiens] 6 4 113.2 5.9 0.669 0.936964 
Q15828 Cystatin-M [OS=Homo sapiens] 21 2 16.5 8.09 0.668 0.936964 
Q03154 Aminoacylase-1 [OS=Homo sapiens] 26 7 45.9 6.18 1.704 0.93757 
P27169 Serum paraoxonase/arylesterase 1 [OS=Homo sapiens] 10 2 39.7 5.22 0.673 0.943888 
A0A0C4DH68 immunoglobulin kappa variable 2-24 [OS=Homo sapiens] 33 2 13.1 8.53 0.674 0.944801 
P98164 
Low-density lipoprotein receptor-related protein 2 [OS=Homo 
sapiens] 
16 57 521.6 5.08 1.649 0.947073 
P01042-2 Isoform LMW of Kininogen-1 [OS=Homo sapiens] 56 22 47.9 6.65 0.675 0.947073 
P35908 Keratin, type II cytoskeletal 2 epidermal [OS=Homo sapiens] 47 22 65.4 8 1.687 0.947073 
P15309-1 Prostatic acid phosphatase [OS=Homo sapiens] 43 17 44.5 6.24 0.676 0.947073 
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P49221 protein-glutamine gamma-glutamyltransferase 4 [OS=Homo sapiens] 23 10 77.1 6.76 0.676 0.947073 
P02753 Retinol-binding protein 4 [OS=Homo sapiens] 47 8 23 6.07 0.681 0.947073 
P14384 Carboxypeptidase M [OS=Homo sapiens] 16 6 50.5 7.36 0.683 0.947073 
P05362 Intercellular adhesion molecule 1 [OS=Homo sapiens] 16 6 57.8 7.99 1.649 0.947073 
Q7Z5L0-1 
Vitelline membrane outer layer protein 1 homolog [OS=Homo 
sapiens] 
55 6 21.5 5.07 0.678 0.947073 
O96009 Napsin-A [OS=Homo sapiens] 29 6 45.4 6.61 1.686 0.947073 
P11279 Lysosome-associated membrane glycoprotein 1 [OS=Homo sapiens] 12 5 44.9 8.75 1.668 0.947073 
P30086 phosphatidylethanolamine-binding protein 1 [OS=Homo sapiens] 49 5 21 7.53 1.631 0.947073 
P29622 Kallistatin [OS=Homo sapiens] 12 5 48.5 7.75 0.695 0.947073 
Q9H8L6 Multimerin-2 [OS=Homo sapiens] 4 4 104.3 5.86 1.633 0.947073 
P23528 Cofilin-1 [OS=Homo sapiens] 32 3 18.5 8.09 1.63 0.947073 
P15848 arylsulfatase B [OS=Homo sapiens] 9 3 59.6 8.21 1.652 0.947073 
Q9NQ84-2 
Isoform 2 of G-protein coupled receptor family C group 5 member C 
[OS=Homo sapiens] 
6 2 49.4 8.43 0.686 0.947073 
Q5VW32 BRO1 domain-containing protein BROX [OS=Homo sapiens] 8 2 46.4 7.65 0.694 0.947073 
Q9BVM4 gamma-glutamylaminecyclotransferase [OS=Homo sapiens] 17 2 17.3 6.87 1.689 0.947073 
P45877 peptidyl-prolyl cis-trans isomerase C [OS=Homo sapiens] 10 2 22.7 8.4 0.7 0.947073 
P55290-4 Isoform 4 of Cadherin-13 [OS=Homo sapiens] 13 7 83.3 5.12 0.703 0.951903 
P16278 Beta-galactosidase [OS=Homo sapiens] 24 12 76 6.57 1.622 0.953633 
Q8NBJ4 Golgi membrane protein 1 [OS=Homo sapiens] 24 7 45.3 4.97 1.616 0.959848 
P23083 Immunoglobulin heavy variable 1-2 [OS=Homo sapiens] 11 2 13.1 9.13 0.71 0.966978 
P03973 Antileukoproteinase [OS=Homo sapiens] 20 2 14.3 8.75 1.609 0.967162 
Q92820 Gamma-glutamyl hydrolase [OS=Homo sapiens] 39 9 35.9 7.11 1.605 0.970534 
P21333 Filamin-A [OS=Homo sapiens] 2 2 280.6 6.06 1.604 0.970534 
P00734 Prothrombin [OS=Homo sapiens] 33 16 70 5.9 1.598 0.977717 
Q9H3G5 Probable serine carboxypeptidase CPVL [OS=Homo sapiens] 20 9 54.1 5.62 1.597 0.977717 
Q07075 Glutamyl aminopeptidase [OS=Homo sapiens] 20 16 109.2 5.47 1.595 0.978879 
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O43707 Alpha-actinin-4 [OS=Homo sapiens] 11 7 104.8 5.44 1.594 0.978879 
P54802 alpha-N-acetylglucosaminidase [OS=Homo sapiens] 44 23 82.2 6.65 0.718 0.979427 
P35527 Keratin, type I cytoskeletal 9 [OS=Homo sapiens] 51 20 62 5.24 0.718 0.979427 
P04217 Alpha-1B-glycoprotein [OS=Homo sapiens] 55 15 54.2 5.86 0.728 0.979427 
P05090 apolipoprotein D [OS=Homo sapiens] 37 10 21.3 5.15 0.725 0.979427 
P07602-3 Isoform Sap-mu-9 of Prosaposin [OS=Homo sapiens] 15 7 58.4 5.14 1.55 0.979427 
P53634-1 Dipeptidyl peptidase 1 [OS=Homo sapiens] 22 7 51.8 6.99 1.552 0.979427 
P19652 Alpha-1-acid glycoprotein 2 [OS=Homo sapiens] 48 9 23.6 5.11 0.718 0.979427 
P09525 annexin A4 [OS=Homo sapiens] 25 6 35.9 6.13 1.546 0.979427 
O95865 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 [OS=Homo 
sapiens] 
27 5 29.6 6.01 0.723 0.979427 
P43251-2 Isoform 2 of Biotinidase [OS=Homo sapiens] 13 5 61.5 6.14 0.74 0.979427 
P62937 peptidyl-prolyl cis-trans isomerase A [OS=Homo sapiens] 36 5 18 7.81 1.557 0.979427 
P00915 carbonic anhydrase 1 [OS=Homo sapiens] 31 5 28.9 7.12 1.575 0.979427 
P24821 Tenascin [OS=Homo sapiens] 3 4 240.7 4.89 1.579 0.979427 
Q9H665 IGF-like family receptor 1 [OS=Homo sapiens] 16 4 37.9 7.08 1.585 0.979427 
O75503 Ceroid-lipofuscinosis neuronal protein 5 [OS=Homo sapiens] 9 3 41.5 7.4 1.586 0.979427 
Q6UXG3 CMRF35-like molecule 9 [OS=Homo sapiens] 11 3 36 5.92 0.732 0.979427 
Q9UGN4-1 CMRF35-like molecule 8 [OS=Homo sapiens] 11 3 33.2 5.49 1.571 0.979427 
Q14508 WAP four-disulfide core domain protein 2 [OS=Homo sapiens] 27 3 13 4.84 1.547 0.979427 
P23526-1 Adenosylhomocysteinase [OS=Homo sapiens] 9 3 47.7 6.34 1.568 0.979427 
P45880-1 
Isoform 1 of Voltage-dependent anion-selective channel protein 2 
[OS=Homo sapiens] 
12 3 33.4 7.59 0.735 0.979427 
Q8IUL8 Cartilage intermediate layer protein 2 [OS=Homo sapiens] 3 2 126.2 8.22 0.736 0.979427 
Q16651 prostasin [OS=Homo sapiens] 10 2 36.4 5.85 0.74 0.979427 
P35052 Glypican-1 [OS=Homo sapiens] 6 2 61.6 7.3 1.564 0.979427 
Q9NU53 Glycoprotein integral membrane protein 1 [OS=Homo sapiens] 9 2 36.8 4.91 0.731 0.979427 
P28799 Granulins [OS=Homo sapiens] 8 2 63.5 6.83 1.587 0.979427 
 88 
 
P00739-2 Isoform 2 of Haptoglobin-related protein [OS=Homo sapiens] 27 11 43 7.08 1.573 0.979427 
P20138-1 Myeloid cell surface antigen CD33 [OS=Homo sapiens] 8 2 39.8 8.38 0.738 0.979427 
P62805 histone H4 [OS=Homo sapiens] 41 4 11.4 11.36 0.742 0.983015 
P02768-1 Serum albumin [OS=Homo sapiens] 74 52 69.3 6.28 0.901 0.983586 
O60494 cubilin [OS=Homo sapiens] 23 52 398.5 5.35 1.21 0.983586 
P02787 Serotransferrin [OS=Homo sapiens] 72 45 77 7.12 1.514 0.983586 
P15144 aminopeptidase N [OS=Homo sapiens] 40 34 109.5 5.48 1.348 0.983586 
P00450 Ceruloplasmin [OS=Homo sapiens] 40 33 122.1 5.72 0.879 0.983586 
P01133-1 Pro-epidermal growth factor [OS=Homo sapiens] 28 31 133.9 5.85 0.997 0.983586 
O43451 Maltase-glucoamylase, intestinal [OS=Homo sapiens] 20 27 209.7 5.5 1.257 0.983586 
P07911-5 Isoform 5 of Uromodulin [OS=Homo sapiens] 50 26 73.5 5.26 0.768 0.983586 
P02751 fibronectin [OS=Homo sapiens] 17 24 262.5 5.71 0.867 0.983586 
P01833 Polymeric immunoglobulin receptor [OS=Homo sapiens] 42 24 83.2 5.74 0.883 0.983586 
P04264 Keratin, type II cytoskeletal 1 [OS=Homo sapiens] 45 26 66 8.12 0.823 0.983586 
P13645 Keratin, type I cytoskeletal 10 [OS=Homo sapiens] 49 26 58.8 5.21 1.175 0.983586 
P98160 
Basement membrane-specific heparan sulfate proteoglycan core 
protein [OS=Homo sapiens] 
8 22 468.5 6.51 0.836 0.983586 
Q9BXP8-1 Pappalysin-2 [OS=Homo sapiens] 19 21 198.4 5.47 1.396 0.983586 
P02774-3 Isoform 3 of Vitamin D-binding protein [OS=Homo sapiens] 47 18 55.1 5.74 1.254 0.983586 
P12109 Collagen alpha-1(VI) chain [OS=Homo sapiens] 27 17 108.5 5.43 0.972 0.983586 
P01011-1 Alpha-1-antichymotrypsin [OS=Homo sapiens] 49 17 47.6 5.52 0.97 0.983586 
P01023 alpha-2-macroglobulin [OS=Homo sapiens] 17 17 163.2 6.46 0.884 0.983586 
P00747 Plasminogen [OS=Homo sapiens] 34 17 90.5 7.24 0.832 0.983586 
Q12805 
EGF-containing fibulin-like extracellular matrix protein 1 [OS=Homo 
sapiens] 
49 16 54.6 5.07 1.31 0.983586 
P08473 Neprilysin [OS=Homo sapiens] 28 16 85.5 5.73 1.352 0.983586 
P02647 Apolipoprotein A-I [OS=Homo sapiens] 52 16 30.8 5.76 0.947 0.983586 
P02671-1 Fibrinogen alpha chain [OS=Homo sapiens] 28 15 94.9 6.01 0.969 0.983586 
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P05155-3 Isoform 3 of Plasma protease C1 inhibitor [OS=Homo sapiens] 31 15 55.7 6.4 0.927 0.983586 
P19320-1 Vascular cell adhesion protein 1 [OS=Homo sapiens] 27 15 81.2 5.22 0.87 0.983586 
Q12907 Vesicular integral-membrane protein VIP36 [OS=Homo sapiens] 42 14 40.2 6.95 0.806 0.983586 
O00391 Sulfhydryl oxidase 1 [OS=Homo sapiens] 25 14 82.5 8.92 0.955 0.983586 
P22891-2 Isoform 2 of Vitamin K-dependent protein Z [OS=Homo sapiens] 36 14 47 6.04 1.363 0.983586 
P02679 Fibrinogen gamma chain [OS=Homo sapiens] 43 12 51.5 5.62 1.46 0.983586 
P07355-2 Isoform 2 of Annexin A2 [OS=Homo sapiens] 43 12 40.4 8.37 0.935 0.983586 
P22792 Carboxypeptidase n subunit 2 [OS=Homo sapiens] 33 12 60.5 5.99 1.2 0.983586 
Q16270-1 Insulin-like growth factor-binding protein 7 [OS=Homo sapiens] 48 12 29.1 7.9 1.196 0.983586 
P05154 Plasma serine protease inhibitor [OS=Homo sapiens] 37 12 45.6 9.26 0.793 0.983586 
O95336 6-phosphogluconolactonase [OS=Homo sapiens] 67 11 27.5 6.05 0.858 0.983586 
P11117 Lysosomal acid phosphatase [OS=Homo sapiens] 26 11 48.3 6.74 1.009 0.983586 
P15586 N-acetylglucosamine-6-sulfatase [OS=Homo sapiens] 23 10 62 8.31 1.252 0.983586 
P14543-1 Nidogen-1 [OS=Homo sapiens] 15 10 136.3 5.29 0.971 0.983586 
P0DOX5 immunoglobulin gamma-1 heavy chain [OS=Homo sapiens] 48 18 49.3 8.72 1.537 0.983586 
P02649 Apolipoprotein E [OS=Homo sapiens] 37 10 36.1 5.73 0.943 0.983586 
Q8WZ75-1 Roundabout homolog 4 [OS=Homo sapiens] 12 10 107.4 6.64 1.165 0.983586 
P02750 Leucine-rich alpha-2-glycoprotein [OS=Homo sapiens] 45 10 38.2 6.95 0.893 0.983586 
P0DOX2 Immunoglobulin alpha-2 heavy chain [OS=Homo sapiens] 49 15 48.9 6.81 0.889 0.983586 
P01876 immunoglobulin heavy constant alpha 1 [OS=Homo sapiens] 63 13 37.6 6.51 0.886 0.983586 
P02749 Beta-2-glycoprotein 1 [OS=Homo sapiens] 40 9 38.3 7.97 0.784 0.983586 
P19013 Keratin, type II cytoskeletal 4 [OS=Homo sapiens] 29 10 57.3 6.61 1.246 0.983586 
P02538 Keratin, type II cytoskeletal 6A [OS=Homo sapiens] 28 13 60 8 1.275 0.983586 
Q9BYE9 Cadherin-related family member 2 [OS=Homo sapiens] 9 9 141.5 4.5 1.166 0.983586 
P12830 Cadherin-1 [OS=Homo sapiens] 16 9 97.4 4.73 0.793 0.983586 
P19022 Cadherin-2 [OS=Homo sapiens] 16 9 99.7 4.81 0.951 0.983586 
P16444 dipeptidase 1 [OS=Homo sapiens] 34 9 45.6 6.15 1.49 0.983586 
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P05156 Complement factor I [OS=Homo sapiens] 21 9 65.7 7.5 1.389 0.983586 
P60174 Triosephosphate isomerase [OS=Homo sapiens] 44 8 30.8 5.92 1.392 0.983586 
Q9HAT2 sialate O-acetylesterase [OS=Homo sapiens] 19 8 58.3 7.33 1.341 0.983586 
P06733-1 alpha-enolase [OS=Homo sapiens] 31 10 47.1 7.39 1.334 0.983586 
P02763 Alpha-1-acid glycoprotein 1 [OS=Homo sapiens] 49 10 23.5 5.02 1.134 0.983586 
P43652 Afamin [OS=Homo sapiens] 19 8 69 5.9 1.24 0.983586 
P27487 Dipeptidyl peptidase 4 [OS=Homo sapiens] 12 8 88.2 6.04 0.988 0.983586 
P13646 Keratin, type I cytoskeletal 13 [OS=Homo sapiens] 33 15 49.6 4.96 0.908 0.983586 
P01859 Immunoglobulin heavy constant gamma 2 [OS=Homo sapiens] 62 14 35.9 7.59 0.956 0.983586 
P01871-2 Isoform 2 of Immunoglobulin heavy constant mu [OS=Homo sapiens] 21 8 51.9 6.15 1.198 0.983586 
P19835-1 Bile salt-activated lipase [OS=Homo sapiens] 16 8 79.3 5.34 1.015 0.983586 
P08174-7 
Isoform 7 of Complement decay-accelerating factor [OS=Homo 
sapiens] 
22 8 59 8.78 0.998 0.983586 
Q01459 Di-N-acetylchitobiase [OS=Homo sapiens] 28 7 43.7 6.64 0.91 0.983586 
Q96NY8 Nectin-4 [OS=Homo sapiens] 18 7 55.4 5.38 0.802 0.983586 
P68871 Hemoglobin subunit beta [OS=Homo sapiens] 90 12 16 7.28 0.766 0.983586 
Q8NCC3 Group XV phospholipase A2 [OS=Homo sapiens] 22 7 46.6 6.73 1.207 0.983586 
Q9NZP8 Complement C1r subcomponent-like protein [OS=Homo sapiens] 20 7 53.5 7.2 0.751 0.983586 
O00560-1 Syntenin-1 [OS=Homo sapiens] 40 7 32.4 7.53 1.356 0.983586 
P13647 keratin, type II cytoskeletal 5 [OS=Homo sapiens] 22 11 62.3 7.74 1.146 0.983586 
P15289-2 Isoform 2 of Arylsulfatase A [OS=Homo sapiens] 28 7 44.9 5.87 1.183 0.983586 
P50895 Basal cell adhesion molecule [OS=Homo sapiens] 15 7 67.4 5.81 1.009 0.983586 
Q8NFZ8 Cell adhesion molecule 4 [OS=Homo sapiens] 26 7 42.8 6.3 0.973 0.983586 
P18065 Insulin-like growth factor-binding protein 2 [OS=Homo sapiens] 31 7 34.8 7.5 1.444 0.983586 
P43121 Cell surface glycoprotein MUC18 [OS=Homo sapiens] 19 7 71.6 5.76 1.003 0.983586 
P15311 Ezrin [OS=Homo sapiens] 27 13 69.4 6.27 1.372 0.983586 
P00558 phosphoglycerate kinase 1 [OS=Homo sapiens] 26 7 44.6 8.1 1.349 0.983586 
Q99715-1 Collagen alpha-1(XII) chain [OS=Homo sapiens] 4 7 332.9 5.53 1.244 0.983586 
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O14498 
Immunoglobulin superfamily containing leucine-rich repeat protein 
[OS=Homo sapiens] 
23 7 46 5.15 0.756 0.983586 
P08294 Extracellular superoxide dismutase [Cu-Zn] [OS=Homo sapiens] 37 7 25.8 6.61 0.814 0.983586 
P11142-1 Heat shock cognate 71 kDa protein [OS=Homo sapiens] 18 8 70.9 5.52 1.502 0.983586 
P07195 L-lactate dehydrogenase B chain [OS=Homo sapiens] 25 8 36.6 6.05 1.353 0.983586 
P06280 alpha-galactosidase A [OS=Homo sapiens] 20 7 48.7 5.6 1.139 0.983586 
Q96RW7-1 Hemicentin-1 [OS=Homo sapiens] 2 7 613 6.49 0.784 0.983586 
P16870 Carboxypeptidase E [OS=Homo sapiens] 26 7 53.1 5.14 0.858 0.983586 
Q99519 sialidase-1 [OS=Homo sapiens] 17 6 45.4 5.88 1.203 0.983586 
P04406 glyceraldehyde-3-phosphate dehydrogenase [OS=Homo sapiens] 28 6 36 8.46 1.436 0.983586 
P15941-2 Isoform 2 of Mucin-1 [OS=Homo sapiens] 6 6 122.9 7.56 1.235 0.983586 
P26992 Ciliary neurotrophic factor receptor subunit alpha [OS=Homo sapiens] 30 6 40.6 6.76 0.841 0.983586 
P01034 Cystatin-C [OS=Homo sapiens] 45 6 15.8 8.75 1.275 0.983586 
P01019 Angiotensinogen [OS=Homo sapiens] 20 6 53.1 6.32 1.215 0.983586 
P30530 Tyrosine-protein kinase receptor UFO [OS=Homo sapiens] 11 6 98.3 5.43 1.166 0.983586 
P17900 Ganglioside GM2 activator [OS=Homo sapiens] 41 6 20.8 5.31 1.196 0.983586 
P08779 Keratin, type I cytoskeletal 16 [OS=Homo sapiens] 33 12 51.2 5.05 0.922 0.983586 
P00352 Retinal dehydrogenase 1 [OS=Homo sapiens] 17 6 54..8 6.73 1.463 0.983586 
P04004 Vitronectin [OS=Homo sapiens] 15 6 54.3 5.8 1.155 0.983586 
Q8IV08 Phospholipase D3 [OS=Homo sapiens] 16 6 54.7 6.47 0.871 0.983586 
Q02487 Desmocollin-2 [OS=Homo sapiens] 11 6 99.9 5.34 1.127 0.983586 
Q96DA0 Zymogen granule protein 16 homolog B [OS=Homo sapiens] 43 6 22.7 7.39 0.842 0.983586 
P06727 Apolipoprotein A-IV [OS=Homo sapiens] 18 6 45.4 5.38 0.931 0.983586 
O75594 peptidoglycan recognition protein 1 [OS=Homo sapiens] 53 6 21.7 8.59 0.961 0.983586 
P06870-1 Kallikrein-1 [OS=Homo sapiens] 54 6 28.9 4.83 0.911 0.983586 
Q9Y2E5 Epididymis-specific alpha-mannosidase [OS=Homo sapiens] 8 6 11.9 7.24 1.266 0.983586 
P19440 glutathione hydrolase 1 proenzyme [OS=Homo sapiens] 14 6 61.4 7.12 1.468 0.983586 
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Q9Y5Y7 
Lymphatic vessel endothelial hyaluronic acid receptor 1 [OS=Homo 
sapiens] 
20 6 35.2 8.28 1.148 0.983586 
P54760 Ephrin type-B receptor 4 [OS=Homo sapiens] 9 6 108.2 6.9 0.924 0.983586 
Q12913-1 Receptor-type tyrosine-protein phosphatase eta [OS=Homo sapiens] 8 6 145.9 5.58 0.917 0.983586 
P09603 Macrophage colony-stimulating factor 1 [OS=Homo sapiens] 14 6 60.1 5.29 1.362 0.983586 
Q8IYS5-7 
Isoform 7 of Osteoclast-associated immunoglobulin-like receptor 
[OS=Homo sapiens] 
30 5 30.9 6.52 1.294 0.983586 
P16152 Carbonyl reductase [NADPH] 1 [OS=Homo sapiens] 25 5 30.4 8.32 1.233 0.983586 
Q9UNN8 Endothelial protein C receptor [OS=Homo sapiens] 26 5 26.7 7.18 0.929 0,983586 
Q96IU4 Protein ABHD14B [OS=Homo sapiens] 33 5 22.3 6.4 0.973 0.983586 
P42785-2 Isoform 2 of Lysosomal Pro-X carboxypeptidase [OS=Homo sapiens] 15 5 58.1 7.4 1..013 0.983586 
P30041 Peroxiredoxin-6 [OS=Homo sapiens] 29 5 25 6.38 1.368 0.983586 
O00241 Signal-regulatory protein beta-1 [OS=Homo sapiens] 17 5 43.2 6.52 0.935 0.983586 
P10619 lysosomal protective protein [OS=Homo sapiens] 12 5 54.4 6.61 1.441 0.983586 
P22105-4 Isoform 5 of Tenascin-X [OS=Homo sapiens] 2 5 458.2 5.17 1.527 0.983586 
P08236 beta-glucuronidase [OS=Homo sapiens] 9 5 74.7 7.02 1.239 0.983586 
Q9H6S3 
epidermal growth factor receptor kinase substrate 8-like protein 2 
[OS=Homo sapiens] 
10 5 80.6 6.84 0.899 0.983586 
Q9Y646 Carboxypeptidase Q [OS=Homo sapiens] 15 5 51.9 6.18 1.452 0.983586 
P08138-2 
Isoform 2 of Tumor necrosis factor receptor superfamily member 16 
[OS=Homo sapiens] 
26 5 35.7 4.7 1.327 0.983586 
Q8NHP8 Putative phospholipase B-like 2 [OS=Homo sapiens] 11 5 65.4 6.8 1.193 0.983586 
P36955 Pigment epithelium-derived factor [OS=Homo sapiens] 15 5 46.3 6.38 0.983 0.983586 
P33908 
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA [OS=Homo 
sapiens] 
11 5 72.9 6.47 0.934 0.983586 
P00918 Carbonic anhydrase 2 [OS=Homo sapiens] 25 5 29.2 7.4 1.279 0.983586 
P14618 Pyruvate kinase PKM [OS=Homo sapiens] 16 5 57.9 7.84 1.268 0.983586 
P25705-1 ATP synthase subunit alpha, mitochondrial [OS=Homo sapiens] 12 5 59.7 9.13 1.286 0.983586 
P04745 alpha-amylase 1 [OS=Homo sapiens] 60 20 57.7 6.93 0.801 0.983586 
P68104 Elongation factor 1-alpha 1 [OS=Homo sapiens] 15 5 50.1 9.01 1.214 0.983586 
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Q03403 Trefoil factor 2 [OS=Homo sapiens] 51 5 14.3 5.81 0.789 0.983586 
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic [OS=Homo sapiens] 16 6 46.6 7.01 1.414 0.983586 
P01591 Immunoglobulin J chain [OS=Homo sapiens] 37 5 18.1 5.24 0.802 0.983586 
P22352 Glutathione peroxidase 3 [OS=Homo sapiens] 28 5 25.5 8.13 0.894 0.983586 
P08758 annexin A5 [OS=Homo sapiens] 16 5 35.9 5.05 1.002 0.983586 
Q86UN3 Reticulon-4 receptor-like 2 [OS=Homo sapiens] 14 5 46.1 7.62 0.91 0.983586 
P61970 nuclear transport factor 2 [OS=Homo sapiens] 69 5 14.5 5.38 1.464 0.983586 
Q86T13 C-type lectin domain family 14 member A [OS=Homo sapiens] 18 5 51.6 6.35 0.896 0.983586 
Q08174-2 Isoform 2 of Protocadherin-1 [OS=Homo sapiens] 6 5 133.6 5.06 1.016 0.983586 
Q8WUM4-2 
Isoform 2 of Programmed cell death 6-interacting protein [OS=Homo 
sapiens] 
9 5 96.7 6.52 1.225 0.983586 
P06576 ATP synthase subunit beta, mitochondrial [OS=Homo sapiens] 13 5 56.5 5.4 1.411 0.983586 
Q96AP7 Endothelial cell-selective adhesion molecule [OS=Homo sapiens] 15 4 41.2 9.32 0.817 0.983586 
O00462 Beta-mannosidase [OS=Homo sapiens] 5 4 100.8 5.52 1.376 0.983586 
O43505 beta-1,4-glucuronyltransferase 1 [OS=Homo sapiens] 12 4 47.1 7.2 0.985 0.983586 
Q9BY67-3 Isoform 3 of Cell adhesion molecule 1 [OS=Homo sapiens] 18 4 51.5 4.87 1.016 0.983586 
P53990-5 Isoform 5 of IST1 homolog [OS=Homo sapiens] 14 4 41.5 5.57 1.185 0.983586 
P17050 alpha-N-acetylgalactosaminidase [OS=Homo sapiens] 11 4 46.5 5.19 1.466 0.983586 
O95967 
EGF-containing fibulin-like extracellular matrix protein 2 [OS=Homo 
sapiens] 
14 4 49.4 4.94 0.75 0.983586 
P63104 14-3-3 protein zeta/delta [OS=Homo sapiens] 26 5 27.7 4.79 1.477 0.983586 
P13987 CD59 glycoprotein [OS=Homo sapiens] 20 4 14.2 6.48 0.854 0.983586 
P15328 Folate receptor alpha [OS=Homo sapiens] 18 4 29.8 7.97 1.244 0.983586 
Q06830 peroxiredoxin-1 [OS=Homo sapiens] 31 5 22.1 8.13 1.421 0.983586 
Q13421-2 Isoform 3 of Mesothelin [OS=Homo sapiens] 8 4 71.4 7.36 1.181 0.983586 
O75340 programmed cell death protein 6 [OS=Homo sapiens] 35 4 21.9 5.4 1.309 0.983586 
P10153 Non-secretory ribonuclease [OS=Homo sapiens] 22 4 18.3 8.73 0.913 0.983586 
Q6UVK1 Chondroitin sulfate proteoglycan 4 [OS=Homo sapiens] 2 4 250.4 5.47 1.192 0.983586 
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Q9ULI3 Protein HEG homolog 1 [OS=Homo sapiens] 6 4 147.4 6.18 1.52 0.983586 
P30740 Leukocyte elastase inhibitor [OS=Homo sapiens] 13 4 42.7 6.28 1.14 0.983586 
P09211 Glutathione S-transferase P [OS=Homo sapiens] 30 4 23.3 5.64 0.39 0.983586 
P12111 Collagen alpha-3(VI) chain [OS=Homo sapiens] 2 4 343.5 6.68 1.425 0.983586 
P32119 Peroxiredoxin-2 [OS=Homo sapiens] 23 5 21.9 5.97 1.448 0.983586 
P23142-4 Isoform C of Fibulin-1 [OS=Homo sapiens] 9 4 74.4 5.24 0.816 0.983586 
P39060-3 Collagen alpha-1(XVIII) chain [OS=Homo sapiens] 5 4 178.1 6.01 0.819 0.983586 
P13727 Bone marrow proteoglycan [OS=Homo sapiens] 25 4 25.2 6.76 1.465 0.983586 
P15291 Beta-1,4-galactosyltransferase 1 [OS=Homo sapiens] 19 4 43.9 8.65 1.167 0.983586 
P08697-1 Alpha-2-antiplasmin [OS=Homo sapiens] 15 4 54.5 6.29 1.286 0.983586 
P56537 eukaryotic translation initiation factor 6 [OS=Homo sapiens] 33 4 26.6 4.68 1.392 0.983586 
P16070 CD44 antigen [OS=Homo sapiens] 7 4 81.5 5.33 0.987 0.983586 
P15814 Immunoglobulin lambda-like polypeptide 1 [OS=Homo sapiens] 23 3 22.9 10.07 1.243 0.983586 
P05937 Calbindin [OS=Homo sapiens] 13 3 30 4.83 1.001 0.983586 
P15151-1 Poliovirus receptor [OS=Homo sapiens] 10 3 45.3 6.52 1.193 0.983586 
O75144-2 Isoform 2 of ICOS ligand [OS=Homo sapiens] 14 3 34.2 5.11 1.205 0.983586 
P16112 Aggrecan core protein [OS=Homo sapiens] 1 3 250 4.18 0.987 0.983586 
P78324-2 
Isoform 2 of Tyrosine-protein phosphatase non-receptor type substrate 
1 [OS=Homo sapiens] 
28 8 55.4 6.98 0.875 0.983586 
P11021 78 kDa glucose-regulated protein [OS=Homo sapiens] 7 3 72.3 5.16 0.93 0.983586 
P01040 Cystatin-A [OS=Homo sapiens] 53 3 11 5.5 0.753 0.983586 
Q9UGT4 Sushi domain-containing protein 2 [OS=Homo sapiens] 5 3 90.2 6.28 0.759 0.983586 
P17931 Galectin-3 [OS=Homo sapiens] 15 3 26.1 8.56 1.25 0.983586 
P04433 Immunoglobulin kappa variable 3-11 [OS=Homo sapiens] 52 3 12.6 4.96 0.816 0.983586 
Q07507 Dermatopontin [OS=Homo sapiens] 18 3 24 4.82 1.152 0.983586 
P01619 Immunoglobulin kappa variable 3-20 [OS=Homo sapiens] 47 5 12.5 4.96 0.884 0.983586 
Q14982-4 
Isoform 4 of Opioid-binding protein/cell adhesion molecule 
[OS=Homo sapiens] 
14 3 38.8 6.55 1.333 0.983586 
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P98172 ephrin-B1 [OS=Homo sapiens] 16 3 38 8.94 1.32 0.983586 
P40189-1 Interleukin-6 receptor subunit beta [OS=Homo sapiens] 4 3 103.5 5.95 0.978 0.983586 
P01860 Immunoglobulin heavy constant gamma 3 [OS=Homo sapiens] 35 11 41.3 7.9 1.425 0.983586 
Q96FE7-1 Phosphoinositide-3-kinase-interacting protein 1 [OS=Homo sapiens] 14 3 28.2 5.01 1.185 0.983586 
Q6P531 glutathione hydrolase 6 [OS=Homo sapiens] 11 3 50.5 6.07 0.796 0.983586 
Q13228-4 Isoform 4 of Selenium-binding protein 1 [OS=Homo sapiens] 8 3 56.8 6.48 1.459 0.983586 
Q9P121-4 Isoform 4 of Neurotrimin [OS=Homo sapiens] 12 3 39.2 8 1.333 0.983586 
P23284 peptidyl-prolyl cis-trans isomerase B [OS=Homo sapiens] 16 3 23.7 9.41 0.761 0.983586 
P61916 Epididymal secretory protein E1 [OS=Homo sapiens] 32 3 16.6 7.65 0.841 0.983586 
P0C0L5 Complement C4-B [OS=Homo sapiens] 33 40 192.6 7.27 0.799 0.983586 
P61026 ras-related protein rab-10 [OS=Homo sapiens] 17 3 22.5 8.38 1.236 0.983586 
Q7Z3B1 Neuronal growth regulator 1 [OS=Homo sapiens] 14 3 38.7 6.21 0.896 0.983586 
Q08345-5 
Isoform 4 of Epithelial discoidin domain-containing receptor 1 
[OS=Homo sapiens] 
4 3 101.7 6.83 0.857 0.983586 
Q496F6 CMRF35-like molecule 2 [OS=Homo sapiens] 18 3 22.9 8 1.371 0.983586 
Q9UIB8 SLAM family member 5 [OS=Homo sapiens] 15 3 38.8 7.06 1.422 0.983586 
P31997 
carcinoembryonic antigen-related cell adhesion molecule 8 
[OS=Homo sapiens] 
12 3 38.1 7.39 1.134 0.983586 
P06865 Beta-hexosaminidase subunit alpha [OS=Homo sapiens] 8 4 60.7 5.16 1.39 0.983586 
Q14515 SPARC-like protein 1 [OS=Homo sapiens] 6 3 75.2 4.81 0.902 0.983586 
P50897 Palmitoyl-protein thioesterase 1 [OS=Homo sapiens] 16 3 34.2 6.52 1.4 0.983586 
Q969P0 Immunoglobulin superfamily member 8 [OS=Homo sapiens] 7 3 65 8 1.467 0.983586 
Q9HB40 Retinoid-inducible serine carboxypeptidase [OS=Homo sapiens] 8 3 50.8 5.81 1.469 0.983586 
P19827-1 Inter-alpha-trypsin inhibitor heavy chain H1 [OS=Homo sapiens] 6 3 101.3 6.79 1.391 0.983586 
Q9UBX5 Fibulin-5 [OS=Homo sapiens] 7 3 50.1 4.73 0.905 0.983586 
P40925-3 Isoform 3 of Malate dehydrogenase, cytoplasmic [OS=Homo sapiens] 11 3 38.6 7.71 1.318 0.983586 
P22223-1 Cadherin-3 [OS=Homo sapiens] 5 3 91.4 4.75 1.523 0.983586 
O00584 Ribonuclease T2 [OS=Homo sapiens] 12 3 29.5 7.08 0.772 0.983586 
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P0DOX8 Immunoglobulin lambda-1 light chain [OS=Homo sapiens] 37 6 22.8 6.76 0.826 0.983586 
P13591-2 Neural cell adhesion molecule 1 [OS=Homo sapiens] 4 2 94.5 4.87 0.941 0.983586 
P31431-1 syndecan-4 [OS=Homo sapiens] 14 2 21.6 4.5 1.174 0.983586 
P19801-2 
Isoform 2 of Amiloride-sensitive amine oxidase [copper-containing] 
[OS=Homo sapiens] 
4 2 87.2 7.17 0.899 0.983586 
Q9UBR2 Cathepsin Z [OS=Homo sapiens] 9 2 33.8 7.11 0.828 0.983586 
P07737 profilin-1 [OS=Homo sapiens] 19 2 15 8.27 1.203 0.983586 
P55000 Secreted Ly-6/uPAR-related protein 1 [OS=Homo sapiens] 52 2 11.2 5.33 1.202 0.983586 
P29972-1 aquaporin-1 [OS=Homo sapiens] 13 2 28.5 7.42 0.898 0.983586 
P04899-4 
Isoform sGi2 of Guanine nucleotide-binding protein G(i) subunit 
alpha-2 [OS=Homo sapiens] 
7 2 41.5 5.99 0.848 0.983586 
P12821-1 Angiotensin-converting enzyme [OS=Homo sapiens] 2 2 149.6 6.39 1.507 0.983586 
Q9UN70-1 Protocadherin gamma-C3 [OS=Homo sapiens] 2 2 101 5.21 1.012 0.983586 
Q9GZX9 Twisted gastrulation protein homolog 1 [OS=Homo sapiens] 16 2 25 5.34 0.923 0.983586 
Q00796 Sorbitol dehydrogenase [OS=Homo sapiens] 10 2 38.3 7.97 1.33 0.983586 
Q96J84-2 Isoform 2 of Kin of IRRE-like protein 1 [OS=Homo sapiens] 4 2 85 5.73 1.155 0.983586 
Q8TDQ1-6 Isoform 6 of CMRF35-like molecule 1 [OS=Homo sapiens] 8 2 32.6 5.99 0.996 0.983586 
O15393-2 Isoform 2 of Transmembrane protease serine 2 [OS=Homo sapiens] 6 2 57.7 5.44 0.793 0.983586 
Q04695 Keratin, type I cytoskeletal 17 [OS=Homo sapiens] 15 7 48.1 5.02 1.136 0.983586 
A0A0A0MS15 immunoglobulin heavy variable 3-49 [OS=Homo sapiens] 17 2 13 8.62 1.303 0.983586 
Q8N6Q3 CD177 antigen [OS=Homo sapiens] 10 2 46.3 6.29 1.257 0.983586 
P07359 Platelet glycoprotein Ib alpha chain [OS=Homo sapiens] 3 2 71.5 6.29 0.817 0.983586 
A6NI73-1 
Leukocyte immunoglobulin-like receptor subfamily A member 5 
[OS=Homo sapiens] 
15 2 32.7 6.99 1.372 0.983586 
Q01469 Fatty acid-binding protein, epidermal [OS=Homo sapiens] 13 2 15.2 7.01 0.874 0.983586 
Q8TF66-2 
Isoform 2 of Leucine-rich repeat-containing protein 15 [OS=Homo 
sapiens] 
4 2 65 6.71 0.755 0.983586 
P00748 Coagulation factor XII [OS=Homo sapiens] 6 2 67.7 7.74 1.364 0.983586 
P06312 immunoglobulin kappa variable 4-1 [OS=Homo sapiens] 20 2 13.4 5.25 0.841 0.983586 
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P13533 myosin-6 [OS=Homo sapiens] 3 5 223.6 5.73 0.781 0.983586 
A0A0C4DH25 immunoglobulin kappa variable 3D-20 [OS=Homo sapiens] 28 4 12.5 4.59 0.823 0.983586 
Q9UM22 Mammalian ependymin-related protein 1 [OS=Homo sapiens] 10 2 25.4 6.6 0.963 0.983586 
P0DOX7 immunoglobulin kappa light chain [OS=Homo sapiens] 53 10 23.4 7.17 0.993 0.983586 
P01599 Immunoglobulin kappa variable 1-17 [OS=Homo sapiens] 23 2 12.8 8.68 0.826 0.983586 
P01614 Immunoglobulin kappa variable 2D-40 [OS=Homo sapiens] 28 3 13.3 4.61 0951 0.983586 
P61224-1 Ras-related protein Rap-1b [OS=Homo sapiens] 13 2 20.8 5.78 1.364 0.983586 
O43278 Kunitz-type protease inhibitor 1 [OS=Homo sapiens] 4 2 58.4 6.29 0.91 0.983586 
P14174 Macrophage Migration inhibitory factor [OS=Homo sapiens] 17 2 12.5 7.88 1.262 0.983586 
O00592 Podocalyxin [OS=Homo sapiens] 4 2 58.6 5.49 1.188 0.983586 
P18669 Phosphoglycerate mutase 1 [OS=Homo sapiens] 14 2 28.8 7.18 1.395 0.983586 
P07996 thrombospondin-1 [OS=Homo sapiens] 2 2 129.3 4.94 1.349 0.983586 
P31025 Lipocalin-1 [OS=Homo sapiens] 13 2 19.2 5.58 1.222 0.983586 
Q8N4F0 BPI fold-containing family B member 2 [OS=Homo sapiens] 7 2 49.1 8.72 1.381 0.983586 
P07998 Ribonuclease pancreatic [OS=Homo sapiens] 30 2 17.6 8.79 1.124 0.983586 
P11684 Uteroglobin [OS=Homo sapiens] 42 2 10 5.06 0.799 0.983586 
P63000-2 
Isoform B of Ras-related C3 botulinum toxin substrate 1 [OS=Homo 
sapiens] 
9 2 23.5 8.63 1.389 0.983586 
Q6UX71-1 Plexin domain-containing protein 2 [OS=Homo sapiens] 5 2 59.5 6.46 1.184 0.983586 
P08727 Keratin, type I cytoskeletal 19 [OS=Homo sapiens] 16 6 44.1 5.14 0.865 0.983586 
Q99574 Neuroserpin [OS=Homo sapiens] 6 2 46.4 4.91 0.789 0.983586 
Q9UMR5-3 Isoform 3 of Lysosomal thioesterase PPT2 [OS=Homo sapiens] 10 2 34.8 6.46 1.284 0.983586 
P36957 
Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial [OS=Homo 
sapiens] 
4 2 48.7 8.95 0.863 0.983586 
Q14393-1 Growth arrest-specific protein 6 [OS=Homo sapiens] 5 2 79.6 6.21 1.352 0.983586 
P04430 Immunoglobulin kappa variable 1-16 [OS=Homo sapiens] 29 2 12.6 8.16 0.958 0.983586 
P21266 glutathione S-transferase Mu 3 [OS=Homo sapiens] 11 2 26.5 5.54 0.852 0.983586 
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Q5T2W1-1 
Na(+)/H(+) exchange regulatory cofactor NHE-RF3 [OS=Homo 
sapiens] 
6 2 57.1 5.55 1.129 0.983586 
A0A0B4J1X5 immunoglobulin heavy variable 3-74 [OS=Homo sapiens] 25 4 12.8 8.66 0.908 0.983586 
P05413 Fatty acid-binding protein, heart [OS=Homo sapiens] 17 2 14.8 6.8 1.186 0.983586 
P41181 aquaporin-2 [OS=Homo sapiens] 8 2 28.8 6.93 1.298 0.983586 
P01594 Immunoglobulin kappa variable 1-33 [OS=Homo sapiens] 34 2 12.8 4.78 0.947 0.983586 
A0A0B4J2D9 immunoglobulin kappa variable 1D-13 [OS=Homo sapiens] 29 2 12.6 7.84 0.765 0.983586 
P34059 N-acetylgalactosamine-6-sulfatase [OS=Homo sapiens] 8 2 58 6.74 1.249 0.983586 
A0A075B6S5 immunoglobulin kappa variable 1-27 [OS=Homo sapiens] 54 3 12.7 8.29 1.2 0.983586 
Q9BRT3 migration and invasion enhancer 1 [OS=Homo sapiens] 30 2 12.4 4.37 1.213 0.983586 
O43633 charged multivesicular body protein 2a [OS=Homo sapiens] 9 2 25.1 5.97 0.888 0.983586 
P01701 immunoglobulin lambda variable 1-51 [OS=Homo sapiens] 32 2 12.2 7.03 1.242 0.983586 
P55285-1 Cadherin-6 [OS=Homo sapiens] 3 2 88.3 4.93 1.324 0.983586 
Q9HD89 resistin [OS=Homo sapiens] 24 2 11.4 6.86 1.371 0.983586 
A0A0C4DH38 immunoglobulin heavy variable 5-51 [OS=Homo sapiens] 38 3 12.7 8.27 1.007 0.983586 
P05026 
Sodium/potassium-transporting ATPase subunit beta-1 [OS=Homo 
sapiens] 
9 2 35 8.53 1.512 0.983586 
P61626 lysozyme c [OS=Homo sapiens] 27 2 16.5 9.16 1.018 0.983917 
P00738 Haptoglobin [OS=Homo sapiens] 57 20 45.2 6.58 1.122 0.984832 
Q14624-1 Inter-alpha-trypsin inhibitor heavy chain H4 [OS=Homo sapiens] 28 25 10.3.3 6.98 1.12 0.985411 
P01033 Metalloproteinase inhibitor 1 [OS=Homo sapiens] 20 3 23.2 8.1 1.021 0.986584 
O14773 Tripeptidyl-peptidase 1 [OS=Homo sapiens] 19 6 61.2 6.48 1.031 0.992101 
P08572 Collagen alpha-2(IV) chain [OS=Homo sapiens] 2 3 167.4 8.66 1.111 0.992101 
P01834 immunoglobulin kappa constant [OS=Homo sapiens] 90 10 11.8 6.52 1.031 0.992101 
P04432 Immunoglobulin kappa variable 1D-39 [OS=Homo sapiens] 29 2 12.7 8.66 1.029 0.992101 
P09619 Platelet-derived growth factor receptor beta [OS=Homo sapiens] 2 2 123.9 4.98 1.026 0.992101 
P00751-1 Complement factor B [OS=Homo sapiens] 26 15 85.5 7.06 1.106 0.992505 
Q92692-1 Nectin-2 [OS=Homo sapiens] 16 7 57.7 4.82 1.105 0992505 
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P09564 T-cell antigen CD7 [OS=Homo sapiens] 10 2 25.4 7.27 1.103 0.992505 
P01700 Immunoglobulin lambda variable 1-47 [OS=Homo sapiens] 25 2 12.3 5.91 1.105 0.992505 
P19438-5 
Isoform 5 of Tumor necrosis factor receptor superfamily member 1A 
[OS=Homo sapiens] 
14 2 24.2 7.71 1.104 0.992505 
P02533 Keratin, type I cytoskeletal 14 [OS=Homo sapiens] 34 13 51.5 5.16 1.037 0.993555 
P10253 lysosomal alpha-glucosidase [OS=Homo sapiens] 39 23 105.3 6 1.046 0.997917 
P02790 Hemopexin [OS=Homo sapiens] 60 19 51.6 7.02 1.08 0.997917 
P01008 Antithrombin-III [OS=Homo sapiens] 37 14 52.6 6.71 1.047 0.997917 
Q6EMK4 vasorin [OS=Homo sapiens] 25 11 71.7 7.39 1.06 0.997917 
P35555 Fibrillin-1 [OS=Homo sapiens] 4 10 312 4.93 1.096 0.997917 
P21796 
voltage-dependent anion-selective channel protein 1 [OS=Homo 
sapiens] 
30 7 30.8 8.54 1.097 0.997917 
P02748 complement component C9 [OS=Homo sapiens] 17 7 63.1 5.59 1.056 0.997917 
P08195-4 
Isoform 4 of 4F2 cell-surface antigen heavy chain [OS=Homo 
sapiens] 
13 6 71.1 4.97 1.055 0.997917 
Q8TDQ0 Hepatitis A virus cellular receptor 2 [OS=Homo sapiens] 26 6 33.4 5.72 1.083 0.997917 
O43895 Xaa-Pro aminopeptidase 2 [OS=Homo sapiens] 10 5 75.6 6.04 1.08 0.997917 
P62979 Ubiquitin-40S ribosomal protein S27a [OS=Homo sapiens] 30 4 18 9.64 1.062 0.997917 
Q6GTX8 
Leukocyte-associated immunoglobulin-like receptor 1 [OS=Homo 
sapiens] 
13 4 31.4 5.63 1.063 0.997917 
P38606 V-type proton ATPase catalytic subunit A [OS=Homo sapiens] 8 3 68.3 5.52 1.096 0.997917 
Q7Z7M0 
Multiple epidermal growth factor-like domains protein 8 [OS=Homo 
sapiens] 
2 3 302.9 6.87 1.055 0.997917 
Q9HBB8-1 Cadherin-related family member 5 [OS=Homo sapiens] 6 3 88.2 4.93 1.049 0.997917 
P04040 catalase [OS=Homo sapiens] 5 2 59.7 7.39 1.086 0.997917 
P01824 immunoglobulin heavy variable 4-39 [OS=Homo sapiens] 20 2 13.9 9.26 1.092 0.997917 
P10909-2 Isoform 2 of Clusterin [OS=Homo sapiens] 27 13 57.8 6.68 1.072 0.998298 
Q14315 Filamin-C [OS=Homo sapiens] 1 2 290.8 5.97 1.066 0.998298 
Q08380 Galectin-3-binding protein [OS=Homo sapiens] 34 16 65.3 5.27 1.067 0.998434 
P13598 Intercellular adhesion molecule 2 [OS=Homo sapiens] 15 3 30.6 7.43 1.071 0.998434 
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Q5JS37 NHL repeat-containing protein 3 [OS=Homo sapiens] 18 4 38.3 6.43 1.069 1 
Q07837 
neutral and basic amino acid transport protein rBAT [OS=Homo 
sapiens] 
4 2 78.8 5.96   
P50053 Ketohexokinase [OS=Homo sapiens] 8 2 32.5 6.32   
P07358 Complement component C8 beta chain [OS=Homo sapiens] 6 2 67 8.13   
P09488 Glutathione S-transferase Mu 1 [OS=Homo sapiens] 14 2 25.7 6.7   
 
 
